U.S. patent number 7,981,926 [Application Number 11/990,323] was granted by the patent office on 2011-07-19 for fluorotaxoids.
This patent grant is currently assigned to Research Foundation of State University of New York. Invention is credited to Iwao Ojima.
United States Patent |
7,981,926 |
Ojima |
July 19, 2011 |
**Please see images for:
( Certificate of Correction ) ** |
Fluorotaxoids
Abstract
The invention relates to fluorinated second generation taxoid
compounds, pharmaceutical formulations thereof, and their use for
inhibiting the growth of cancer cells in a mammal.
Inventors: |
Ojima; Iwao (Port Jefferson,
NY) |
Assignee: |
Research Foundation of State
University of New York (Albany, NY)
|
Family
ID: |
37758214 |
Appl.
No.: |
11/990,323 |
Filed: |
August 11, 2006 |
PCT
Filed: |
August 11, 2006 |
PCT No.: |
PCT/US2006/031413 |
371(c)(1),(2),(4) Date: |
June 23, 2008 |
PCT
Pub. No.: |
WO2007/021957 |
PCT
Pub. Date: |
February 22, 2007 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20090118355 A1 |
May 7, 2009 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
60707665 |
Aug 12, 2005 |
|
|
|
|
Current U.S.
Class: |
514/449; 549/511;
549/510 |
Current CPC
Class: |
A61P
35/00 (20180101); C07D 305/14 (20130101) |
Current International
Class: |
C07D
305/14 (20060101); A61K 31/337 (20060101) |
Field of
Search: |
;549/510,511
;514/449 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
PCT/US2004/036027 |
|
May 2005 |
|
WO |
|
PCT/US2005/004715 |
|
Sep 2005 |
|
WO |
|
Primary Examiner: Andres; Janet L.
Assistant Examiner: Covington; Raymond
Attorney, Agent or Firm: Hoffmann & Baron, LLP
Government Interests
The present invention was made with government support under Grant
No. R01 GM 42798 awarded by the National Institute of General
Medical Sciences and Grant No. RO1 CA10331 awarded by the National
Cancer Institute. The United States government has certain rights
in this invention.
Parent Case Text
The present application claims priority to U.S. Provisional
Application No. 60/707,665 filed on Aug. 12, 2005, which
application is incorporated herein by reference in its entirety.
Claims
We claim:
1. A taxoid compound represented by the formula: ##STR00019##
wherein: R.sup.1 represents an alkyl, alkenyl, alkylamino,
dialkylamino, or alkoxy group having one to six carbon atoms; a
non-aromatic carbocyclic alkyl or alkenyl group having three to
seventeen ring carbon atoms; a carbocyclic aryl group having six to
eighteen ring carbon atoms; a non-aromatic heterocyclic group
having three to seventeen ring carbon atoms or a heterocyclic aryl
group having five to seventeen ring carbon atoms, wherein said
cyclic groups can be unfused or fused, and unsubstituted or
substituted; R.sup.2 represents a hydrogen; alkyl, alkenyl, alkoxy,
alkenyloxy, acyloxy, alkylthio, alkenylthio, alkylamino or
dialkylamino having one to six carbon atoms; halogen; fluoroalkyl
group having one to three fluorine atoms and one to three carbon
atoms; hydroxyl; carboxyl; amino or azido; R.sup.3 and R.sup.5 both
represent hydrogen, or R.sup.3 and R.sup.5 are linked as a cyclic
carbonate; R.sup.4 represents an alkyl or alkenyl group having one
to six carbon atoms; or a cycloalkyl or cycloalkenyl group having
three to seven ring carbon atoms; and R.sup.6 represents a
fluorovinyl, difluorovinyl, or trifluorovinyl group having the
formula ##STR00020## wherein R.sup.7, R.sup.8, and R.sup.9 each
independently represent a hydrogen or fluoro group, provided that
at least one of R.sup.7, R.sup.8, and R.sup.9 represents a fluoro
group.
2. The taxoid compound according to claim 1, wherein R.sup.7
represents hydrogen and each of R.sup.8 and R.sup.9 represents a
fluoro group.
3. The taxoid compound according to claim 1, wherein R.sup.4
represents tert-butyl.
4. The taxoid compound according to claim 3, represented by the
formula: ##STR00021## wherein R.sup.1 represents an alkyl, alkenyl,
alkylamino, dialkylamino, or alkoxy group having one to six carbon
atoms; a non-aromatic carbocyclic alkyl or alkenyl group having
three to seventeen ring carbon atoms; a carbocyclic aryl group
having six to eighteen ring carbon atoms; a non-aromatic
heterocyclic group having three to seventeen ring carbon atoms or a
heterocyclic aryl group having five to seventeen ring carbon atoms,
wherein said cyclic groups can be unfused or fused, and
unsubstituted or substituted; and wherein R.sup.2 represents a
hydrogen; alkyl, alkenyl, alkoxy, alkenyloxy, acyloxy, alkylthio,
alkenylthio, alkylamino or dialkylamino having one to six carbon
atoms; halogen; fluoroalkyl group having one to three fluorine
atoms and one to three carbon atoms; hydroxyl; carboxyl; amino or
azido.
5. The taxoid compound according to claim 4, wherein R.sup.1
represents methyl, ethyl, methoxy, dimethylamino or cyclopropyl and
R.sup.2 represents hydrogen, methyl, methoxy, chloro, fluoro or
azido.
6. The taxoid compound according to claim 4, wherein R.sup.1
represents methyl, ethyl, methoxy, dimethylamino or cyclopropyl and
R.sup.2 represents methoxy.
7. The taxoid compound according to claim 4, wherein R.sup.1
represents methyl, ethyl, methoxy, dimethylamino or cyclopropyl and
R.sup.2 represents azido.
8. The taxoid compound according to claim 4, wherein R.sup.1
represents methyl, ethyl, methoxy, dimethylamino or cyclopropyl and
R.sup.2 represents chloro.
9. The taxoid compound according to claim 4, wherein R.sup.1
represents methyl, ethyl, methoxy, dimethylamino or cyclopropyl and
R.sup.2 represents fluoro.
10. A pharmaceutical composition comprising a taxoid compound
according to claim 1 and a pharmaceutically acceptable carrier.
11. A method for inhibiting the growth of cancer cells in a mammal
in need thereof, the method comprising administering to the mammal
an effective amount of a taxoid compound according to claim 1.
Description
BACKGROUND OF THE INVENTION
First generation taxoid compounds such as paclitaxel (Taxol.RTM.)
and docetaxel (Taxotere.RTM.) have gained prominence as some of the
most efficacious anticancer drugs. See E. K. Rowinsky, Annual
Review of Medicine 1997, 48, 353; M. Suffness, Taxol Science and
Applications; CRC Press: New York, 1995.
Second generation taxoid compounds with orders of magnitude higher
potency have also been developed. See U.S. Pat. Nos. 6,096,909,
6,100,411, 6,458,976, and 6,500,858 to I. Ojima; G. I. Georg, T.
Chen, I. Ojima, and D. M. Vyas (Eds.), "Taxane Anticancer Agents:
Basic Science and Current Status," ACS Symp. Series 583; American
Chemical Society, Washington, D.C., 1995); I. Ojima, et al, Bioorg.
Med. Chem. Lett., 1999, 9, 3423-3428; I. Ojima, et al, J. Med.
Chem., 1996, 39, 3889-3896; and I. Ojima, G. D. Vite, K.-H. Altmann
(Eds.), "Anticancer Agents: Frontiers in Cancer Chemotherapy," ACS
Symp. Series 796, American Chemical Society, Washington, D.C.,
2001.
While these and other second generation taxoids have shown a high
degree of efficacy in the treatment of various forms of cancer,
there is a continuing need for improving the activity, metabolic
stability, and mode of action of these compounds. There is a
particular need to improve the efficacy of second generation taxoid
compounds against multi-drug resistance (MDR) in the treatment of
cancer. There is also a need for new taxoid compounds having less
acute side effects and higher metabolic stability.
SUMMARY OF THE INVENTION
These, and other objectives as will be apparent to those of
ordinary skill in the art, have been achieved by providing a
compound having the formula:
##STR00001## wherein: R.sup.1 represents an alkyl, alkenyl,
alkylamino, dialkylamino, or alkoxy group having one to six carbon
atoms; a non-aromatic carbocyclic alkyl or alkenyl group having
three to seventeen ring carbon atoms; a carbocyclic aryl group
having six to eighteen ring carbon atoms; a non-aromatic
heterocyclic group having three to seventeen ring carbon atoms or a
heterocyclic aryl group having five to seventeen ring carbon atoms,
wherein said cyclic groups can be unfused or fused, and
unsubstituted or substituted;
R.sup.2 represents a hydrogen; alkyl, alkenyl, alkoxy, alkenyloxy,
acyloxy, alkylthio, alkenylthio, alkylamino or dialkylamino having
one to six carbon atoms; halogen; fluoroalkyl group having one to
three fluorine atoms and one to three carbon atoms; hydroxyl;
carboxyl; amino or azido; R.sup.3 and R.sup.5 both represent
hydrogen, or R.sup.3 and R.sup.5 are linked as a cyclic
carbonate;
R.sup.4 represents an alkyl or alkenyl group having one to six
carbon atoms; or a cycloalkyl or cycloalkenyl group having three to
seven ring carbon atoms; and
R.sup.6 represents a fluorovinyl, difluorovinyl, or trifluorovinyl
group having the formula
##STR00002## wherein R.sup.7, R.sup.8, and R.sup.9 each
independently represent a hydrogen or fluoro group, provided that
at least one of R.sup.7, R.sup.8, and R.sup.9 represents a fluoro
group.
In another embodiment, the invention provides a pharmaceutical
composition comprising the fluorotaxoid composition.
The invention is further directed to a method for inhibiting the
growth of cancer cells in a mammal in need thereof, the method
comprising administering to the mammal an effective amount of the
fluorotaxoid compound described above.
DETAILED DESCRIPTION OF THE INVENTION
In one aspect, the invention relates to second generation
fluorotaxoid compounds. The fluorotaxoid compounds contain a
fluorovinyl, difluorovinyl, or trifluorovinyl group at the C3'
position of a second generation taxoid compound.
In a preferred embodiment, the taxoid compounds of the invention
are represented by the formula:
##STR00003##
In formula (1), R.sup.1 represents a hydrocarbon group selected
from an alkyl, alkenyl, alkylamino, dialkylamino, or alkoxy group
having one to six carbon atoms; a non-aromatic carbocyclic alkyl or
alkenyl group having three to seventeen ring carbon atoms; an aryl
group having six to eighteen ring carbon atoms; or a non-aromatic
heterocyclic group having three to seventeen ring carbon atoms; or
a heteroaryl group having five to seventeen ring carbon atoms.
These acyclic and cyclic hydrocarbon groups may be attached to the
fluorotaxoid at any carbon position.
Some examples of suitable straight-chained alkyl groups include
methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl.
Some examples of suitable branched alkyl groups include iso-propyl,
iso-butyl, sec-butyl, t-butyl, 1-methylbutyl, 2-methylbutyl,
3-methylbutyl (isopentyl), 1,1-dimethylpropyl, 1,2-dimethylpropyl,
2,2-dimethylpropyl (neopentyl), 1-methylpentyl, 2-methylpentyl,
3-methylpentyl, and 4-methylpentyl.
Some examples of suitable straight-chained alkenyl groups include
vinyl, 2-propen-1-yl, 2-buten-1-yl, 3-buten-1-yl, 2-penten-1-yl,
3-penten-1-yl, 1,3-pentadien-1-yl, 4-penten-1-yl, 2-hexen-1-yl,
3-hexenyl, 4-hexen-1-yl, and 5-hexen-1-yl.
Some examples of suitable branched alkenyl groups include
propen-2-yl, 1-buten-2-yl, 2-buten-2-yl, 1-buten-3-yl,
1-penten-2-yl, 1-penten-3-yl, 1-penten-4-yl, 2-penten-2-yl,
2-penten-3-yl, 2-penten-4-yl, 1-buten-3-methyl-2-yl,
1-buten-3-methyl-3-yl, 2-buten-2-methyl-1-yl,
2-buten-2-methyl-3-yl, 2-buten-2-methyl-4-yl, 2-buten-2-methylenyl,
2-buten-2,3-dimethyl-1-yl, 1-hexen-2-yl, 1-hexen-3-yl,
1-hexen-4-yl, 1-hexen-5-yl, 2-hexen-3-yl, 2-hexen-4-yl,
2-hexen-5-yl, 3-hexen-2-yl, 3-hexen-3-yl, 1-penten-3-methyl-2-yl,
1-penten-3-methyl-3-yl, 1-penten-3-methyl-4-yl,
2-penten-3-methyl-2-yl, and 2-penten-3-methyl-4-yl.
Some examples of suitable alkylamino groups include methylamino,
ethylamino, n-propylamino, iso-propylamino, n-butylamino,
sec-butylamino, iso-butylamino, tert-butylamino, n-pentylamino,
iso-pentylamino, neo-pentylamino, n-hexylamino,
2,3-dimethylbutylamino, cyclopropylamino, cyclobutylamino,
cyclopentylamino, cyclohexylamino, cycloheptylamino,
2-hydroxyethylamino, 2-(2-hydroxyethyleneoxy)-ethylamino,
2-methoxyethylamino, 2-ethoxyethylamino, and
3-hydroxypropylamino.
Some examples of suitable dialkylamino groups include
dimethylamino, methylethylamino, methyl(n-propyl)amino,
methyl(iso-propylamino), methyl(n-butyl)amino,
methyl(iso-butyl)amino, methyl(n-pentyl)amino,
methyl(iso-pentyl)amino, methyl(neopentyl)amino, diethylamino,
ethyl(n-propyl)amino, ethyl(iso-propylamino), ethyl(n-butyl)amino,
ethyl(iso-butyl)amino, di(n-propyl)amino, and
di(iso-propyl)amino.
Some examples of suitable alkoxy groups include methoxy, ethoxy,
n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy,
tert-butoxy, n-pentoxy, 1-methylbutoxy, 2-methylbutoxy,
3-methylbutoxy, n-hexoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy,
2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 1-ethylbutoxy,
2-ethylbutoxy, cyclopropyloxy, cyclobutyloxy,
2,4-dimethylcyclobutyloxy, cyclohexyloxy, cyclopropylmethyloxy,
cyclohexylmethyloxy, and phenoxy.
The non-aromatic carboxylic alkyl or alkenyl groups of R.sup.1 have
three to seventeen ring carbon atoms. Some examples of suitable
non-aromatic carboxylic alkyl groups include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Some examples
of suitable non-aromatic carboxylic alkenyl groups include
cyclobutenyl, cyclobutadienyl, cyclopentenyl, cyclohexenyl,
cyclohexadienyl, cycloheptenyl, and cycloheptadienyl.
The cyclic groups described above can be fused or unfused. The
total number of carbon atoms include carbon atoms from fused
rings.
A preferred unfused carbocyclic aryl group is phenyl. Some examples
of suitable fused aryl groups include naphthyl, phenanthryl,
anthracenyl, triphenylenyl, chrysenyl, and pyrenyl.
The heterocyclic aryl groups have five to seventeen atoms in the
ring with one or more heteroatoms, preferably nitrogen, sulfur, or
oxygen atoms. Some examples of suitable heteroaryl groups include
pyridinyl, pyrimidinyl, triazinyl, imidazolyl, benzimidazolyl,
pyrrolyl, cinnolinyl, phthalazinyl, quinazolinyl, purinyl,
2,6-naphthyridinyl, 1,8-naphthyridinyl, quinolinyl, isoquinolinyl,
carbazolyl, oxazolyl, thiophenyl, thiazolyl, furyl, pyridazinyl,
pyrazolyl, 1,4-diazanaphthalenyl, indolyl, pyrazinyl,
4,5-diazaphenanthrene, and benzoxazole.
R.sup.1 can also be a non-aromatic heterocyclic group. Some
examples of suitable non-aromatic heterocyclic groups include
piperidinyl, piperidinyl-N-oxide, N-methylpiperidinyl, piperazinyl,
1-methylpiperazinyl, piperazinyl-N-oxide, 1-acetylpiperazinyl,
1-(o-tolyl)piperazinyl, homopiperazinyl, and morpholino.
The cycloalkyl, cycloalkenyl, aryl, heteroaryl and non-aromatic
heterocyclic rings described above for R.sup.1 can be substituted
with any of the hydrocarbon groups thus far described.
Some examples of hydrocarbyl-substituted cycloalkyl groups include
2-methylcyclopropyl, 2-ethylcyclopropyl, 2-methylcyclobutyl,
3-methylcyclobutyl, 2-methylcyclopentyl, 2,3-dimethylcyclopentyl,
3-iso-propylcyclopentyl, 2,6-dimethylcyclohexyl,
4-(t-butyl)cyclohexyl, 2-vinylcyclohexyl, 3-allylcyclopentyl,
3,4-diallylcyclopentyl, 1-(4-pyridinyl)piperidinyl,
1-(4-pyridinylmethyl)piperidinyl, 4-(4-pyridinyl)piperidinyl,
4-(4-pyridinyl)piperazin-1-yl, and bicyclohexyl groups.
Some examples of hydrocarbyl-substituted cycloalkenyl groups
include 3-methyl-3-cyclopenten-1-yl,
3,4-dimethyl-3-cyclopenten-1-yl, 2-iso-propyl-2-cyclopenten-1-yl,
2,3-diethyl-2-cyclopenten-1-yl, 4-vinyl-1-cyclohexen-1-yl,
3,4-diethyl-3-cyclopenten-1-yl, and 3,4-diallyl-3-cyclopenten-1-yl
groups.
Some examples of hydrocarbyl-substituted aryl groups include tolyl,
mesityl, xylyl, cumenyl, cymenyl, 3,5-di(t-butyl)phenyl,
2-methylnaphthyl, 2-vinylphenyl, 2-vinylbenzyl, 2-vinylnaphthyl,
4-cyclohexylphenyl, biphenyl, 4-(4-piperidinyl)pyridinyl, and
p-terphenyl groups.
Some examples of hydrocarbyl-substituted heteroaryl groups include
2-methylpyridin-1-yl, 2-ethylpyridin-1-yl, 3-vinylimidazol-1-yl,
2-methylimidazol-1-yl, 2-methylquinoxalin-1-yl,
1-allylbenzotriazolyl, 2,2'-bipyridyl, 4,4'-bipyridyl,
4-methylpyrazinyl, 4-(pyridinylmethyl)-pyridinyl,
4-benzylpyrazinyl, nicotinamidyl, 2-methylfuranyl,
5-methylfurfurylamino, 2-methylthiopheneyl, 4-methyloxazolyl,
2,5-diphenyl-4-methyloxazolyl, and 4-methylthiazolyl groups.
Alternatively, the cycloalkyl, cycloalkenyl, aryl, heteroaryl and
non-aromatic heterocyclic rings described above for R.sup.1 can be
substituted with a halogen, nitro, hydroxyl carboxyl, amino or
azido group.
In formula (1), R.sup.2 can also represent any of the hydrocarbon
groups described above with regard to R.sup.1. For example, R.sup.2
can represent alkyl, such as methyl; alkenyl; alkoxy, such as
methoxy; alkenyloxy; acyloxy; alkylthio; alkenylthio; alkylamino;
or dialkylamino having one to six carbon atoms. Preferably, the
hydrocarbon group contains a maximum of two carbon atoms.
Alternatively, R.sup.2 can also represent hydrogen; a halogen, such
as iodo, bromo, chloro or fluoro; or fluoroalkyl having one to
three fluorine atoms and one to three carbon atoms, for example,
trichloromethyl; hydroxyl; amino; carboxyl; or azido.
R.sup.3 and R.sup.5 both preferably represent hydrogen, or R.sup.3
and R.sup.5 together represent a cyclic carbonate (i.e.,
--O--C(.dbd.O)--O--).
R.sup.4 represents any of the alkyl, alkenyl, cycloalkyl, or
cycloalkenyl groups described above for R.sup.1. Preferably,
R.sup.4 is a tert-butyl group.
In formula (1), R.sup.6 represents a fluorinated vinyl group having
the formula
##STR00004##
In formula (2), R.sup.7, R.sup.8, and R.sup.9 each independently
represent a hydrogen or fluoro group provided that at least one of
R.sup.7, R.sup.8, and R.sup.9 represents a fluoro group. The
fluorinated vinyl group can be a fluorovinyl, difluorovinyl, or
trifluorovinyl group.
The fluorovinyl group can be a 2-fluorovinyl group (--CH.dbd.CHF)
or a 2-fluorovinyl group (--CF.dbd.CH.sub.2). In addition, the
2-fluorovinyl group can be in a cis- or trans-configuration.
The difluorovinyl group can be a 2,2-difluorovinyl group
(--CH.dbd.CF.sub.2) or a 1,2-difluorovinyl group (--CF.dbd.CHF).
The 1,2-difluorovinyl group can have the fluoro substituents in
either a cis- or trans-configuration with respect to each
other.
The trifluorovinyl group corresponds to a 1,2,2-trifluorovinyl
group (--CF.dbd.CF.sub.2).
In a preferred embodiment, the taxoid compounds of the present
invention are represented by the formula:
##STR00005##
In formula (3), R.sup.1 and R.sup.2 are independently as described
above. For example, R.sup.1 can be methyl, ethyl, methoxy,
dimethylamino or cyclopropyl and R.sup.2 can be hydrogen, methyl,
methoxy, chloro, fluoro or azido. More preferably, R.sup.1
represents methyl, ethyl, methoxy, or cyclopropyl, and R.sup.2
represents hydrogen, methoxy, or azido.
Some particularly preferred taxoid compounds of the present
invention include those listed in the table below. These taxoids
have shown particular potency for the inhibition of the growth of
cancer cells as shown in the following table. The results were
obtained according to the methods of Skehan et al (See Skehan et
al., J. Nat. Cancer Inst., 82, 1107 (1990)), as more fully
described in the Examples. The resistance factor (R/S) shown in the
table is a measure of the degree of resistance of a cell line
against a taxoid compound. The resistance factor is a ratio of the
cytoxicity of a taxoid compound against a drug-resistant cell line
(R) as compared to its cytoxicity against a drug-sensitive cell
line (S).
TABLE-US-00001 Highly Potent Difluorovinyl-taxoids (IC.sub.50 nM)
##STR00006## MCF7 MCF7-R Taxoid R X (breast) (breast) R/S
Paclitaxel Me H 1.2 300 250 SB-T-12851 Me H 0.099 0.95 9.6
SB-T-12852-1 cyclo-Pr MeO 0.092 0.48 5.2 SB-T-12853-1 Et MeO 0.34
0.57 1.7 SB-T-12855-1 MeO MeO 0.078 0.50 6.4 SB-T-12851-3 Me
N.sub.3 0.092 0.34 3.7 SB-T-12852-3 cyclo-Pr N.sub.3 0.092 0.45 4.9
SB-T-12855-3 MeO N.sub.3 0.076 0.40 5.3
The fluorotaxoid compounds are either uncharged or in the form of
pharmaceutically acceptable salts. The term "pharmaceutically
acceptable salt" refers to a salt prepared from a suitable compound
and, for example, an acid or a base. The salt is acceptably
non-toxic and has acceptable pharmacokinetics. Such salts are
formed by well known procedures.
Suitable acids for producing salts of the compounds of the
invention include mineral acids and organic acids. Some examples of
mineral acids include hydrochloric, hydriodic, hydrobromic,
phosphoric, metaphosphoric, nitric and sulfuric acids. Some
examples of organic acids include tartaric, acetic, citric, maleic,
malic, benzoic, glycollic, gluconic, gulonic, succinic,
arenesulfonic, e.g. p-toluenesulfonic acids, and the like.
Suitable bases for producing salts of the compounds of the
invention include inorganic bases and organic bases. Some examples
of inorganic bases include ammonia and the hydroxides of lithium,
sodium, potassium, magnesium and calcium. Some examples of organic
bases include primary, secondary, and tertiary alkyl amines.
In another aspect, the invention is directed to a pharmaceutical
composition comprising a compound according to formula (1) or
formula (3) and a pharmaceutically acceptable carrier. Compositions
may, for example, be pills, capsules, solutions, creams, etc.
In this specification, a pharmaceutically acceptable carrier is
considered to be synonymous with a vehicle or an excipient as
understood by practitioners in the art. Examples of carriers
include starch, milk, sugar, certain types of clay, gelatin,
stearic acid or salts thereof, magnesium or calcium stearate, talc,
vegetable fats or oils, gums and glycols.
The pharmaceutical formulation may also include one or more of the
following: a stabilizer, a surfactant, preferably a nonionic
surfactant, and optionally a salt and/or a buffering agent.
The stabilizer can be, for example, an amino acid, e.g., glycine;
or an oligosaccharide, e.g., sucrose, tetralose, lactose or a
dextran. Alternatively, the stabilizer may be a sugar alcohol,
e.g., mannitol; or a combination thereof.
The surfactant may be, for example, an ionic surfactant, such as a
polyacrylate. Alternatively, the surfactant may be a nonionic
surfactant, such as a polyethylene glycol, polyoxyethylene
polyoxypropylene glycol, or polysorbate. Some examples of such
non-ionic surfactants include Tween 20, Tween 80, and Pluronic F-68
at from about 0.001% (w/v) to about 10% (w/v).
The salt or buffering agent may be any salt or buffering agent,
such as, for example, sodium chloride, sodium or potassium
phosphates, citric acid, sodium or potassium citrates, or a mixture
thereof. The buffering agent is useful for maintaining the pH of
the compounds of the invention. The salt and/or buffering agent is
also useful to maintain the osmolality at a level suitable for
administration to a mammal. For example, the salt or buffering
agent can be present at a roughly isotonic concentration of about
150 mM to about 300 mM.
The pharmaceutical compositions of the inventions may additionally
contain one or more conventional additives. Some examples of such
additives include a solubilizer, such as, for example, glycerol; an
antioxidant such as, for example, benzalkonium chloride (a mixture
of quaternary ammonium compounds, known as "quart"), benzyl
alcohol, chloretone or chlorobutanol; an anaesthetic agent such as,
for example, a morphine derivative; or an isotonic agent, etc. As a
further precaution against oxidation or other spoilage, the
compounds of the inventions may be stored under nitrogen gas in
vials sealed with impermeable stoppers.
When aqueous suspensions are used for oral administration,
emulsifying and/or suspending agents are commonly added. In
addition, coloring, sweetening and/or flavoring agents may be added
to the oral compositions.
Pharmaceutical compositions are preferably sterile. The pH of the
solutions can be suitably adjusted and buffered. For intravenous
use, the total concentration of the solute(s) can be controlled in
order to render the preparation isotonic.
Carrier compositions deemed to be suited for topical use include
gels, salves, lotions, creams, ointments and the like. The
compounds can also be incorporated with a support base or matrix or
the like which can be directly applied to skin.
In another aspect, the invention is directed to inhibiting the
growth of cancer cells in a mammal in need thereof. In the method,
an effective amount of a fluorotaxoid compound of the invention is
administered to a mammal.
The cancer cells can be any type of cancer treatable by the taxoid
compounds. For example, the cancer can be breast, ovary, lung,
head, neck, colon, pancreatic, melanoma, brain, prostate, or renal
cancer.
Any mammal in need thereof can be treated in accordance with the
present invention. Mammals include, for example, humans, baboons,
and other primates, as well as pet animals such as dogs and cats,
laboratory animals such as rats and mice, and farm animals such as
horses, sheep, and cows.
The method of the invention comprises administering an effective
amount of a fluorotaxoid compound. An effective amount of the
fluorotaxoid is any amount effective in treating cancer or for
inhibiting the growth of cancer cells in a mammal in need
thereof.
The actual administered amount of the fluorotaxoid compound will
vary according to various factors well known in the art, e.g., the
type of cancer, the particular fluorotaxoid being administered, the
mode of administration, and the particular subject being treated.
The amount required for effective treatment is governed by
pharmacological standards and by the discretion of medical
practitioners in the art. For example, the effective amount can be
determined during clinical and pre-clinical trials by methods
familiar to physicians and clinicians.
The minimum amount of a fluorotaxoid administered to a human is the
lowest amount capable of inhibiting the growth of cancer cells. The
maximum amount is the highest effective amount that does not cause
undesirable or intolerable side effects. The minimum amount can be,
for example, 0.01, 0.05, or 0.1 milligrams per kilogram body weight
per day. The maximum amount can be, for example, 10, 50, or 100
milligrams per kilogram body weight per day. Higher doses may be
employed to treat the cancer to the extent patient tolerance
permits.
The fluorotaxoid formulation may be administered alone or as an
adjunct with other conventional drugs for treating cancer. The
adjunctive drugs can be, for example, chemotherapy drugs. Some
examples of chemotherapy drugs include methotrexate
(Abitrexate.RTM.), fluorouracil (Adrucil.RTM.), hydroxyurea
(Hydrea.RTM.), and mercaptopurine (Purinethol.RTM.).
The fluorotaxoid formulation may be administered by any suitable
method known in the art. Some examples of suitable modes of
administration include oral, systemic, and topical
administration.
For oral administration, liquid or solid oral formulations can be
used, as known in the art. Some examples of formulations suitable
for oral administration include tablets, capsules, pills, troches,
elixirs, suspensions, and syrups.
Systemic administration includes enteral or parenteral modes of
administration, e.g., intravenous; intramuscular; subcutaneous; or
intraperitoneal modes of administration. For example, the
fluorotaxoid formulation may be administered by injection of a
solution or suspension; or intranasally, in the form of, for
example, a nebulizer, liquid mist, or intranasal spray; or
transdermally, in the form of, for example, a patch; or rectally,
in the form of, for example, a suppository; or intrabronchially, in
the form of, for example, an inhaler spray.
Suitable carrier compositions for topical use include gels, salves,
lotions, creams, ointments, and the like. The compounds can also be
incorporated with a support base or matrix or the like which can be
directly applied to skin.
The timing of the administration of the fluorotaxoid formulation
may also be modified. For example, the formulation may be
administered intermittently or by controlled release. Controlled
release administration is a method of drug delivery to achieve a
certain level of the drug over a particular period of time. See,
for example, U.S. Patent Publication No. 2004/0115261, incorporated
herein by reference.
Examples have been set forth below for the purpose of illustration
and to describe the best mode of the invention at the present time.
However, the scope of this invention is not to be in any way
limited by the examples set forth herein.
EXAMPLES
Example 1
Synthesis of 4-difluorovinyl .beta.-lactam
(3R,4S)-3-AcO-.beta.-lactam was prepared through [2+2] ketene-imine
cycloaddition, followed by enzymatic optical resolution of racemic
.beta.-lactam (Scheme III-20).
##STR00007##
The protecting group of the 3-acetoxy moiety of
(3R,4S)-3-AcO-.beta.-lactam was changed to triisopropylsilyl
(TIPS). The resulting
(3R,4S)-1-PMP-3-TIPSO-4-(2-methyl-1-propenyl)azetidin-2-one II-(+)
was subjected to ozonolysis to give
(3R,4S)-1-PMP-3-TIPSO-4-formylazetidin-2-one III-47 (Scheme
III-21).
##STR00008##
Enantiopure (3R,4S)-1-PMP-3-TIPSO-4-formylazetidin-2-one III-47 was
transformed to (3R,4S)-1-PMP-3-TIPSO-4-difluorovinyl-2-one III-48
using CBr.sub.2F.sub.2, hexamethylphosphorous triamide (HMPA), and
Zn in THF (Scheme III-22).
##STR00009##
Finally the PMP group was removed using cerium ammonium nitrate
(CAN) to give enantiopure
(3R,4S)-3-TIPSO-4-difluorovinylazetidin-2-one III-49(+) followed by
carbalkoxylation with di-t-butyl dicarbonate (Boc.sub.2O) to give
desired (3R,4S)--N-Boc-3-TIPSO-4-difluorovinylazetidin-2-one III-50
in excellent yields (Scheme III-24).
##STR00010##
Example 2
Synthesis of C-3' Difluorovinyl Second-Generation Taxoids
The synthesis of baccatin core was performed using literature
methods starting from 10-DAB, yielding III-41 or III-43 in high
yields (Scheme III-25).
##STR00011## ##STR00012##
The ring-opening coupling of .beta.-lactams with modified baccatins
was carried out at -40.degree. C. in THF using LiHMDS. The
subsequent removal of the silyl protecting groups by HF/pyridine
gave the corresponding new difluorovinyl-taxoids III-51 in fairly
good overall yields (Scheme III-26).
##STR00013##
Example 3
1-(4-Methoxyphenyl)-3-triisopropylsilanyloxy-4-(2,2-difluorovinyl)azetidin-
-2-one (III-48)
To a solution of dibromodifluoromethane (1.97 mL, 12.79 mmol) in
THF (85 mL) were added hexamethylphosphorous triamide (4.79 mL,
25.56 mmol) and Zn (1.67 g, 25.56 mmol) at -78.degree. C. The
mixture was allowed to warm slowly to -10.degree. C. The mixture
was stirred for additional 30 min at -10.degree. C. and ether was
added to the reaction mixture. The ether layer was decanted and the
residue was washed with dichloromethane and water. The combined
organic layers were washed with saturated copper sulfate solution
until the blue color stayed, and dried over MgSO.sub.4. The
filtrate was concentrated under reduced pressure to give yellow
oil. Crude material was purified by flash chromatography on silica
gel to yield III-48 (688 mg, 68%): .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. 1.08-1.15 (21H, m), 3.79 (3H, s), 4.54 (1H, ddd,
J=1.5, 6.3, 16.5 Hz), 4.83 (1H, m), 5.14 (1H, d, J=5.1 Hz), 6.87
(2H, d, J=9.0 Hz), 7.32 (2H, d, J=9.0 Hz); .sup.13C NMR
(CDCl.sub.3, 75.5 MHz): .delta. 12.1, 17.9, 54.1 (d, J=8.5 Hz),
55.8, 75.8 (dd, J=5.0, 22.1 Hz), 76.9, 77.4, 114.8, 118.6, 130.9,
156.7, 164.9; .sup.19F NMR (282 MHz, CDCl.sub.3): 8-80.80 (d, 1F,
J=32.7 Hz), -86.34 (dd, 1F, J=2.8 Hz, J=28.2). LRMS (FAB+, m/z):
Calcd. for C.sub.21H.sub.31F.sub.2NO.sub.3Si.H+, 412.2114; Found,
412.2127.
Example 4
3-Triisopropylsiloxy-4-(2,2-difluorovinyl)azetidin-2-one
(III-49)
To a solution of N-PMP-.beta.-lactam (688 mg, 1.67 mmol) in
acetonitrile (50 mL) and water (10 mL), was added dropwise a
solution of ceric ammonium nitrate (3.74 g, 6.69 mmol) in water (40
mL). The reaction mixture was stirred for 2 h. Work up with water
and saturated Na.sub.2SO.sub.3 solution, The aqueous layer was
extracted with EtOAc, and the combined organic layer was washed
with water, dried over MgSO.sub.4 and concentrated. The crude
product was purified on a silica gel column to yield the
.beta.-lactam III-49 as a pale yellow oil (469 mg, 92% yield):
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.03-1.18 (21H, m),
4.44-4.54 (2H, m), 5.04 (1H, dd, J=1.6, 2.4 Hz), 6.59 (1H, bs);
.sup.13C NMR (CDCl.sub.3, 100 MHz): .delta. 12.1, 17.8 (d, J=4.6
Hz), 50.4 (d, J=7.6 Hz), 77.1 (dd, J=15.9, 23.5 Hz), 79.3, 157.6
(t, J=289.9 Hz), 169.4; .sup.19F NMR (282 MHz, CDCl.sub.3):
.beta.-82.33 (d, 1F, J=34.7 Hz), -87.50 (dd, 1F, J=9.3, 25.7
Hz).
Example 5
1-(tert-Butoxycarbonyl)-3-triisopropylsiloxy-4-(2,2-difluorovinyl)azetidin-
-2-one (III-50)
To a solution of 4-(2,2-difluorovinyl)-.beta.-lactam III-49 (469
mg, 1.54 mmol), triethylamine (0.75 mL, 4.62 mmol), and DMAP (43
mg, 0.35 mmol) in CH.sub.2Cl.sub.2 (9 mL), was added Boc.sub.2O
(398 mg, 1.77 mmol) at room temperature. The reaction mixture was
stirred for 18 hours and quenched with water. The reaction mixture
was diluted with ethylacetate (EtOAc) and the organic layer was
washed with brine, dried over MgSO.sub.4, and concentrated under
reduced pressure. Crude material was purified by flash
chromatography on silica gel to give
1-Boc-4-(2,2-difluorovinyl)-.beta.-lactam III-50 as yellow oil (599
mg, 96% yield): [.alpha.].sub.D.sup.20 +24.17 (c 14.4, CHCl.sub.3);
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.04-1.17 (21H, m), 1.49
(9H, s), 4.49 (1H, ddd, J=1.6, 13.8, 23.7 Hz), 4.75 (1H, dddd,
J=0.9, 2.4, 5.1, 9.0 Hz), 5.04 (1H, d, J=5.7 Hz), 6.59 (1 H, bs);
.sup.13C NMR (CDCl.sub.3, 100 MHz): .delta. 12.0, 17.8 (d, J=5.3
Hz), 28.2, 53.6 (d, J=8.4 Hz), 74.5 (dd, J=10.6, 26.5 Hz), 77.2,
83.9, 147.9, 158.5 (t, J=292.2 Hz), 165.3; .sup.19F NMR (282 MHz,
CDCl.sub.3): .delta. -81.20 (d, 1F, J=31.0 Hz), -85.83 (dd, 1F,
J=5.6 Hz, J=29.3). HRMS (FAB+, m/z): Calcd. For
C.sub.19H.sub.33F.sub.2NO.sub.4Si.Na+, 428.2039.
Found, 428.2050.
Example 6
10-Acetyl-3'-dephenyl-3'-(2,2-difluorovinyl)docetaxel, SB-T-12851
(III-51a)
Yield 83%; white solid; mp 155-160.degree. C.;
[.alpha.].sub.D.sup.20 -74.83 (c 2.86, CHCl.sub.3); .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.15 (3H, s, C-16), 1.25 (3H, m,
C-17), 1.30 (9H, s, Boc), 1.68 (3H, s, H-19), 1.75 (bs, 1H, OH),
1.88 (4H, m, H-6b, H-18), 2.24 (3H, s, 10-OAc), 2.33 (2H, m, H-14),
2.39 (3H, s, 4-OAc), 2.49 (1H, d, J=3.6 Hz, OH), 2.55 (1H, ddd,
0.1=6.4, 9.6, 14.8 Hz, H-6a), 3.52 (1H, d, J=5.6 Hz, OH), 3.81 (1H,
d, J=7.2 Hz, H-3), 4.17 (1H, d, J=8.4 Hz, H-20b), 4.28 (1H, s,
J=2.8 Hz, H-2'), 4.31 (1H, d, J=8.4 Hz, H-20a), 4.44 (1H, m, H-7),
4.58 (1H, ddd, J=1.2, 9.6, 24.8 Hz, H-3'-vinyl), 4.87 (1H, t, J=8.8
Hz, H-3'), 4.96 (2H, d, J=9.6, H-5, NH-3'), 5.66 (1H, d, J=7.2 Hz,
H-2), 6.24 (1H, t, J=8.8 Hz, H-13), 6.30 (1H, s, H-10), 7.49 (2H,
t, J=7.6 Hz), 7.61 (1H, t, J=7.2 Hz), 8.11 (2H, d, J=7.6 Hz);
.sup.13C NMR (CDCl.sub.3, 100 MHz) .delta. 9.8, 14.4, 15.1, 21.1,
22.1, 22.5, 26.9, 28.3, 35.7 (d, J=13.7 Hz), 43.5, 45.7, 48.2,
58.8, 72.4, 72.9, 75.8, 76.7, 79.3, 80.7, 81.3, 84.6, 128.9, 129.3,
130.4, 133.4, 133.9, 142.4, 155.1, 156.7, 158.0, 167.3, 170.5,
171.5, 172.7, 203.9; 19F NMR, (CDCl.sub.3, 282 MHz) .delta. -84.29
(1F, dd, J=25.7, 36.4 Hz), -86.22 (1F, dd, J=34.7 Hz); HRMS (FAB+,
m/z): Calcd. for C.sub.41H.sub.51F.sub.2NO.sub.15.H+, 836.3300;
Found, 836.3278.
Example 7
3'-dephenyl-3'-(2,2-difluorovinyl)-10-cyclopropanecarbonyl-docetaxel,
SB-T-12852 (III-51b)
Yield 88%; white solid; mp 171-177.degree. C.;
[.alpha.].sub.D.sup.20 -73.71 (c 5.44, CHCl.sub.3); .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 0.98 (2H, m, CH.sub.2-c-Pr), 1.13
(2H, m, CH.sub.2-c-Pr), 1.15 (3H, s, C-16), 1.26 (3H, m, C-17),
1.30 (9H, s, Boc), 1.66 (3H, s, H-19), 1.78 (2H, m, OH, CH-c-Pr),
1.87 (411, m, H-6b, H-18), 2.31 (2H, m, H-14), 2.38 (311, s,
4-OAc), 2.53 (1H, ddd, J=6.8, 10.0, 15.2 Hz, H-6a), 2.59 (1H, d,
J=3.2 Hz, OH), 3.57 (1H, bs, OH), 3.80 (1H, d, J=6.8 Hz, H-3), 4.17
(1H, d, J=8.4 Hz, H-20b), 4.28 (2H, m, H-2', H-20a), 4.40 (1H, m,
H-7), 4.58 (1H, ddd, J=1.6, 9.6, 24.8 Hz, H-3'-vinyl), 4.87 (1H, t,
J=8.8 Hz, H-3'), 4.97 (2H, m, H-5, NH'), 5.66 (1H, d, j=7.2 Hz,
H-2), 6.24 (1H, t, J=8.0 Hz, H-13), 6.29 (1H, s, H-10), 7.49 (2H,
t, J=7.6 Hz), 7.60 (1H, t, j=7.6 Hz), 8.11 (2H, d, J=7.2 Hz);
.sup.13C NMR (CDCl.sub.3, 100 MHz) .delta. 9.4, 9.6, 9.8, 13.2,
22.5, 27.0, 28.3, 35.7, (d, J=5.3 Hz), 43.5, 45.9, 48.2, 58.8,
72.4, 72.9, 73.3, 75.3, 75.6, 76.6, 79.3, 80.7, 81.3, 84.7, 128.9,
129.3, 130.4, 133.4, 133.9, 142.4, 155.1, 156.7, 167.3, 170.5,
172.6, 175.3, 204.0; .sup.19F NMR, (CDCl.sub.3, 282 MHz) 8-84.32
(1F, dd, J=25.4, 36.4 Hz), -86.30 (1F, dd, J=36.7 Hz); HRMS (FAB+,
m/z): Calcd. for C.sub.43H.sub.53F.sub.2NO.sub.15.H+, 862.3456;
Found, 862.3445.
Example 8
3'-Dephenyl-3'-(2,2-difluorovinyl)-10-propanoyl-docetaxel,
SB-T-12853 (III-51c):
Yield 64%; white solid; mp 175-181.degree. C.;
[.alpha.].sub.D.sup.20 -82.83 (c 5.01, CHCl.sub.3); .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.14 (3H, s, H-16), 1.24 (6H, m,
H-17, H-10-CH.sub.3), 1.30 (9H, s, Boc), 1.67 (3H, s, H-19), 1.78
(1H, m, OH), 1.87 (4H, m, H-6b, H-18), 2.31 (2H, m, H-14), 2.38
(3H, s, 4-OAc), 2.53 (4H, m, H-6a, H-10, CH.sub.2, OH), 3.55 (1H,
bs, OH), 3.81 (1H, d, J=6.8 Hz, H-3), 4.17 (1H, d, J=8.4 Hz,
H-20b), 4.29 (2H, m, H-2', H-20a), 4.39 (1H, m, H-7), 4.56 (1H,
ddd, J=1.6, 9.6, 24.8 Hz, H-3'-vinyl), 4.86 (1H, t, J=8.8 Hz,
H-3'), 4.96 (2H, m, H-5, NH'), 5.66 (1H, d, J=7.2 Hz, H-2), 6.25
(1H, t, J=8.4 Hz, H-13), 6.30 (1H, s, H-10), 7.49 (2H, t, J=7.6
Hz), 7.60 (1H, t, J=7.2 Hz), 8.11 (2H, d, J=7.2 Hz); .sup.13C NMR
(CDCl.sub.3, 100 MHz) .delta. 9.2, 9.8, 15.1, 22.1, 22.5, 26.9,
27.8, 28.4, 35.7 (d, J=12.9 Hz), 43.5, 45.9, 48.2, 58.8, 72.2,
72.4, 72.9, 73.3, 75.3, 75.6, 76.6, 77.4, 79.3, 80.7, 81.3, 84.6,
128.9, 129.3, 130.4, 133.5, 133.9, 142.2, 155.1, 156.7, 167.3,
170.5, 172.6, 174.8, 203.9; .sup.19F NMR, (CDCl.sub.3, 282 MHz)
.delta. -84.31 (1F, dd, J=23.7, 34.7 Hz), -86.23 (1F, dd, J=36.4
Hz); HRMS (FAB+, m/z): Calcd. For
C.sub.42H.sub.53F.sub.2NO.sub.15.H+, 850.3456; Found 850.3450.
Example 9
3'-Dephenyl-3'-(2,2-difluorovinyl)-10-dimethylcarbamoyldocetaxel,
SB-T-12854 (III-51d)
Yield 84%; white solid; mp 166-170.degree. C.;
[.alpha.].sub.D.sup.20 -70.48 (c 6.3, CHCl.sub.3); .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.15 (3H, s, H-16), 1.25 (3H, m,
H-17), 1.30 (9H, s, Boc), 1.67 (3H, s, H-19), 1.84 (1H, m, OH),
1.89 (4H, m, H-6b, H-18), 2.31 (2H, m, H-14), 2.38 (3H, s, 4-OAc),
2.53 (1H, ddd, J=6.8, 9.6, 15.2 Hz, H-6a), 3.64 (1H, d, J=5.6 Hz,
OH), 3.80 (1H, d, J=6.8 Hz, H-3), 4.17 (1H, d, J=8.4 Hz, H-20b),
4.29 (2H, m, H-2', H-20a), 4.44 (1H, m, H-7), 4.57 (1H, dd, J=10.0,
25.2 Hz, H-3'-vinyl), 4.86 (1H, t, J=8.8 Hz, H-3'), 4.97 (1H, d,
J=9.2 Hz, NH-3'), 5.02 (1H, d, J=9.6 Hz, H-5), 5.66 (1H, d, J=7.2
Hz, H-2), 6.24 (2H, m, Hz, H-13, H-10), 7.49 (2H, t, J=7.6 Hz),
7.59 (1H, t, J=7.2 Hz), 8.10 (2H, d, J=7.6 Hz); .sup.13C NMR
(CDCl.sub.3, 100 MHz) .delta. 9.6, 15.1, 22.1, 22.5, 27.1, 28.3,
35.6 (d, J=12.1 Hz), 36.3, 36.8, 43.5, 45.8, 48.2, 58.7, 72.6,
72.9, 73.3, 75.4, 76.3, 76.7, 77.4, 79.4, 80.6, 81.3, 84.6, 128.9,
129.4, 130.4, 133.7, 133.9, 142.7, 155.1, 156.3, 156.5, 167.3,
170.4, 171.3, 203.9; .sup.19F NMR, (CDCl.sub.3, 282 MHz) .delta.
-84.31 (1F, dd, J=25.7, 37.2 Hz), -86.23 (1F, dd, J=36.4 Hz); HRMS
(FAB+, m/z): Calcd. For C.sub.42H.sub.54F.sub.2N.sub.2O.sub.15.H+,
865.3565; Found 865.3562.
Example 10
3'-Dephenyl-3'-(2,2-difluorovinyl)-10-methoxycarbonyldocetaxel,
SB-T-12855 (III-51e)
Yield 90%; white solid; mp 144-148.degree. C.;
[.alpha.].sub.D.sup.20 -77.06 (c 6.8, CHCl.sub.3); .sub.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 1.15 (3H, s, H-16), 1.24 (3H, m,
H-17), 1.29 (9H, s, Boc), 1.68 (3H, s, H-19), 1.78 (1H, m, OH),
1.88 (1H, m, H-6b), 1.91 (3H, s, H-18), 2.31 (2H, m, H-14), 2.39
(3H, s, 4-OAc), 2.53 (2H, m, H-6a, OH), 3.55 (1H, d, J=5.6 Hz, OH),
3.78 (1H, d, J=7.2 Hz, H-3), 3.86 (3H, s, H-10-MeO), 4.17 (1H, d,
J=8.4 Hz, H-20b), 4.29 (2H, m, H-2', H-20a), 4.38 (1H, m, H-7),
4.57 (1H, ddd, J=1.6, 9.6, 24.8 Hz, H-3'-vinyl), 4.86 (1H, t, J=8.8
Hz, H-3'), 4.96 (2H, m, H-5, NH'), 5.66 (1H, d, J=6.8 Hz, H-2),
6.11 (1H, s, H-10), 6.23 (2H, t, J=8.0 Hz, H-13), 7.49 (2H, t,
J=7.6 Hz), 7.60 (1H, t, J=7.2 Hz), 8.10 (2H, d, J=7.2 Hz); .sup.13C
NMR (CDCl.sub.3, 100 MHz) .delta. 9.7, 15.2, 22.1, 22.5, 26.8,
28.3, 35.8 (d, J=23.5 Hz), 43.4, 45.9, 48.2, 55.8, 58.8, 72.1,
72.3, 72.8, 73.3, 75.2, 76.7, 77.4, 78.4, 79.2, 80.7, 81.2, 84.6,
128.9, 129.3, 130.4, 133.0, 133.9, 143.2, 155.1, 155.9, 156.5,
167.3, 170.6, 172.3, 204.1; .sup.19F NMR, (CDCl.sub.3, 282 MHz)
.delta. -84.30 (1F, dd, J=23.7, 34.7 Hz), -86.22 (1F, dd, 34.7 Hz);
HRMS (FAB+, m/z): Calcd. for C.sub.41H.sub.51F.sub.2NO.sub.16.H+,
852.3249; Found 852.3227.
Example 11
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-fluorobenzoyl)-10-acet-
yldocetaxel, SB-T-12851-2 (III-51f)
Yield 72%; white solid; [.alpha.].sub.D.sup.20 -73.29 (c, 7.0
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.15 (3H,
s, C-16), 1.26 (3H, m, C-17), 1.31 (9H, s, Boc), 1.68 (4H, s, H-19,
OH), 1.89 (4H, m, H-6b, H-18), 2.24 (3H, s, 10-OAc), 2.33 (2H, m,
H-14), 2.39 (3H, s, 4-OAc), 2.47 (1H, bs, OH), 2.56 (1H, ddd,
J=7.0, 9.5, 15.0 Hz, H-6a), 3.46 (1H, bs, OH), 3.82 (1H, d, J=7.0
Hz, H-3), 4.16 (1H, d, J=8.5 Hz, H-20b), 4.28 (1H, s, H-2'), 4.31
(1H, d, J=8.5 Hz, H-20a), 4.42 (1H, dd, J=6.5, 11.0 Hz, H-7), 4.58
(1H, ddd, J=1.0, 9.0, 26.0 Hz, H-3' vinyl), 4.90 (2H, m, H-3',
NH-3'), 4.97 (1H, dd, J=2.0, 9.0, H-5), 5.64 (1H, d, J=7.0 Hz,
H-2), 6.23 (1H, t, J=8.0 Hz, H-13), 6.30 (1H, s, H-10), 7.31 (1H,
dt, J=2.0, 8.0 Hz), 7.49 (1H, ddd, J=6.0, 8.5, 13.5 Hz), 7.80 (1H,
d, J=9.0 Hz), 7.91 (1H, d, J=7.5 Hz); .sup.13C NMR (CDCl.sub.3, 100
MHz) .delta. 9.5, 14.8, 20.8, 21.8, 22.2, 26.7, 28.1, 35.5 (d,
J=11.8 Hz), 43.2, 45.6, 58.5, 72.1, 72.5, 73.1, 75.5, 76.3, 79.1,
80.4, 80.9, 84.4, 117.0 (J=23.2 Hz), 120.8 (J=21.1 Hz), 125.9,
130.4 (J=7.8 Hz), 131.2 (J=7.4 Hz), 132.9, 142.2, 154.9, 156.7,
160.9, 164.2, 165.9, 170.2, 171.2, 203.5; .sup.19F NMR,
(CDCl.sub.3, 282 MHz) .delta. -84.23 (1F, dd, J=25.7, 34.7 Hz),
-86.21 (1F, dd, J=36.7 Hz), -111.7 (1F, dd, J=9.3, 14.6 Hz); HRMS
(FAB+, m/z): Calcd. for C.sub.41H.sub.50F.sub.3NO.sub.15.H+,
854.3205; Found, 854.3207.
Example 12
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-fluorobenzoyl)-10-cycl-
opropanecarbonyldocetaxel, SB-T-12852-2 (III-51g)
Yield 78%; white solid; [.alpha.].sub.i).sup.20-77.04 (c 7.1,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 0.99 (2H,
m, CH.sub.2-c-Pr), 1.12 (2H, m, CH.sub.2-c-Pr), 1.15 (3H, s, C-16),
1.26 (3H, m, C-17), 1.30 (9H, s, Boc), 1.66 (3H, s, H-19), 1.77
(2H, m, OH, CH-c-Pr), 1.86 (1H, m, H-6b), 1.87 (3H, s, H-18), 2.33
(2H, m, H-14), 2.39 (3H, s, 4-OAc), 2.53 (1H, ddd, J=7.0, 9.5, 15.5
Hz, H-6a), 2.61 (1H, bs, OH), 3.55 bs, OH), 3.80 (1H, d, J=7.0 Hz,
H-3), 4.17 (1H, d, J=8.0 Hz, H-20b), 4.28 (1H, s, H-2'), 4.29 (1H,
d, J=8.0 Hz, H-20a), 4.40 (1H, dd, J=7.0, 10.5 Hz, H-7), 4.58 (1H,
dd, J=8.5, 23.5 Hz, H-3' vinyl), 4.86 (1H, m, H-3'), 4.97 (2H, m,
H-5, NH'), 5.63 (1H, d, J=7.0 Hz, H-7), 6.24 (1H, t, J=9.5 Hz,
H-13), 6.29 (1H, s, H-10), 7.49 (2H, dt, J=2.5, 8.5 Hz), 7.60 (1H,
ddd, J=6.0, 8.0, 13.5 Hz), 7.78 (1H, d, J=9.5 Hz), 7.90 (1H, d,
J=7.5 Hz); .sup.13C NMR (CDCl.sub.3, 125 MHz) .delta. 9.2, 9.5,
13.0, 14.7, 21.9, 22.2, 26.7, 28.1, 35.5, (d, 5.4 Hz), 43.2, 45.6,
48.0, 58.5, 72.1, 72.5, 73.1, 75.3, 75.5, 76.3, 79.1, 80.4, 80.9,
84.4, 117.0 (d, J=23.8 Hz), 120.8 (d, J=21.2 Hz), 125.9, 130.4 (d,
J=7.7 Hz), 131.3 (d, J=7.7 Hz), 133.0, 142.2, 154.8, 160.9, 164.2,
165.8, 170.2, 175.1, 203.7; .sup.19F NMR, (CDCl.sub.3, 282 MHz)
.delta. -84.22 (1F, dd, J=23.7, 36.7 Hz), -86.20 (1F, d, J=34.7
Hz), -111.72 (1F, dd, J=9.3, 14.6 Hz); HRMS (FAB+, m/z): Calcd. for
C.sub.43H.sub.52F.sub.3NO.sub.15.H+, 880.3362; Found, 880.3346.
Example 13
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-fluorobenzoyl)-10-prop-
anoyldocetaxel, SB-T-12853-2 (III-51h)
Yield 71%; white solid; [.alpha.].sub.D.sup.20 -71.57 (c 8.3,
CHCl.sub.3); .sub.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.14 (3H,
s, H-16), 1.24 (6H, m, H-17, H-10-CH.sub.3), 1.31 (9H, s, Boc),
1.67 (3H, s, H-19), 1.72 (1H, bs, OH), 1.88 (4H, m, H-6b, H-18),
2.32 (2H, m, H-14), 2.39 (3H, s, 4-OAc), 2.53 (3H, m, H-6a, H-10,
CH.sub.2), 3.51 (1H, bs, OH), 3.82 (1H, d, J=7.0 Hz, H-3), 4.16
(1H, d, J=8.5 Hz, H-20b), 4.28 (1H, d, J=1.5 Hz, H-2'), 4.30 (1H,
d, J=8.5 Hz, H-20a), 4.42 (1H, dd, J=6.5, 10.5 Hz, H-7), 4.58 (1H,
ddd, J=1.5, 9.0, 24.5 Hz, H-3'), 4.87 (1H, m, H-3'), 4.96 (2H, m,
H-5, NH'-3'), 5.64 (1H, d, J=6.5 Hz, H-2), 6.23 (1H, t, J=8.0 Hz,
H-13), 6.31 (1H, s, H-10), 7.31 (111, dt, J=2.0, 7.0 Hz), 7.48 (1H,
ddd, J=5.5, 7.5, 13.0 Hz), 7.80 (1H, d, J=8.5 Hz), 7.91 (1H, d,
J=7.5 Hz); .sup.13C NMR (CDCl.sub.3, 125 MHz) .delta. 8.9, 9.5,
14.8, 21.9, 22.2, 26.7, 27.5, 28.1, 35.5 (d, J=10.3 Hz), 43.2,
45.6, 58.5, 72.1, 72.5, 73.1, 75.3, 75.4, 76.3, 79.1, 80.9, 84.4,
116.9 (d, J=23.8 Hz), 120.8 (d, J=21.2 Hz), 125.9, 130.4 (d, J=7.5
Hz), 131.3 (d, J=7.4 Hz), 133.0, 142.1, 154.6, 160.9, 164.2, 165.8,
170.2, 174.6, 203.6; .sup.19F NMR, (CDCl.sub.3, 282 MHz) .delta.
-84.24 (1F, dd, J=23.9, 34.9 Hz), -86.22 (1F, d, J=36.4 Hz); HRMS
(FAB+, m/z): Calcd. for C.sub.42H.sub.52F.sub.3NO.sub.15.H+,
868.3362; Found 868.3352.
Example 14
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-fluorobenzoyl)-10-dime-
thylcarbamoyldocetaxel, SB-T-12854-2 (III-51i)
Yield 71%; white solid; [.alpha.].sub.D''-85.33 (c 1.5,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.16 (3H,
s, H-16), 1.26 (3H, m, H-17), 1.31 (9H, s, Boc), 1.60 (1H, OH),
1.67 (3H, s, H-19), 1.84 (1H, m, OH), 1.89 (1H, m, H-6b), 1.91 (3H,
s, H-18), 2.33 (2H, m, H-14), 2.40 (3H, s, 4-OAc), 2.55 (1H, ddd,
J=6.0, 9.5, 14.5 Hz, H-6a), 2.97 (3H, s, NMe), 3.05 (3H, s, N-Me),
3.40 (1H, s, OH), 3.82 (1H, d, J=7.0 Hz, H-3), 4.17 (1H, d, J=7.5
Hz, H-20b), 4.29 (1H, s, H-2'), 4.31 (1H, d, J=7.5 Hz, H-20a), 4.45
(1H, dd, J=6.0, 10.5 Hz, H-7), 4.58 (1H, m, H-3' vinyl), 4.87 (2H,
bs, H-3', NH-3'), 4.99 (1H, d, J=8.0 Hz, H-5), 5.64 (1H, d, J=7.0
Hz, H-2), 6.26 (2H, m, Hz, H-13, H-10), 7.32 (2H, dt, J=2.0, 8.0
Hz), 7.49 (1H, ddd, J=6.0, 8.5, 13.5 Hz), 7.81 (1H, d, J=9.5 Hz),
7.92 (1H, d, J=8.0 Hz); .sup.13C NMR (CDCl.sub.3, 125 MHz) .delta.
9.3, 14.7, 22.3, 26.9, 28.1, 35.4 (d, J=6.0 Hz), 36.0, 36.6, 43.2,
45.5, 58.5, 72.4, 72.7, 73.1, 75.6, 76.1, 76.4, 77.2, 79.3, 80.4,
81.1, 84.6, 110.7 (d, J=15.1 Hz), 120.8 (d, J=21.2 Hz), 125.9,
130.4 (d, J=7.7 Hz), 131.3 (d, J=7.5 Hz), 133.9, 142.7, 155.1,
157.4, 161.2, 164.1, 166.1, 170.2, 172.3, 205.5; .sup.19F NMR,
(CDCl.sub.3, 282 MHz) 6-84.13 (1F, dd, J=25.4, 36.4 Hz), -86.13
(1F, d, J=36.6 Hz), -111.73 (1F, dd, J=9.3, 14.6 Hz); HRMS (FAB+,
m/z): Calcd. for C.sub.42H.sub.53F.sub.3N.sub.2O.sub.15.H+,
883.3471; Found 883.3433.
Example 15
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-fluorobenzoyl)-10-meth-
oxycarbonyldocetaxel, SB-T-12855-2 (III-51j)
Yield 72%; white solid; [.alpha.].sub.D.sup.20 -70.31 (c 6.5,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.15 (3H,
s, H-16), 1.25 (3H, m, H-17), 1.29 (9H, s, Boc), 1.65 (1H, bs, OH),
1.69 (3H, s, H-19), 1.88 (1H, m, H-6b), 1.92 (3H, s, H-18), 2.31
(2H, m, H-14), 2.39 (3H, s, 4-OAc), 2.46 (1H, bs, OH), 2.57 (1H,
ddd, J=6.0, 9.0, 15 Hz, H-6a), 3.48 (1H, bs, OH), 3.79 (1H, d,
J=7.5 Hz, H-3), 3.87 (3H, s, H-10-MeO), 4.16 (1H, d, J=8.5 Hz,
H-20b), 4.28 (1H, s, H-2'), 4.31 (1H, d, J=8.5 Hz, H-20a), 4.39
(1H, dd, J=7.0, 10.5 Hz, H-7), 4.58 (1H, dd, J=9.0, 24.5 Hz, H-3'
vinyl), 4.87-4.94 (2H, m, H-3', NH-3'), 4.97 (1H, d, J=8.0 Hz,
H-5), 5.65 (1H, d, J=7.0 Hz, H-2), 6.12 (1H, s, H-10), 6.23 (2H, t,
J=9.0 Hz, H-13), 7.31 (1H, dt, J=2.5, 8.5 Hz), 7.49 (1H, ddd,
J=5.0, 7.5, 13.5 Hz,), 7.79 (1H, d, J=8.5 Hz), 7.91 (1H, d, J=8.0
Hz); .sup.13C NMR (CDCl.sub.3, 125 MHz) 9.4, 14.9, 21.8, 22.2,
26.6, 28.1, 35.3, 35.6, 43.1, 45.6, 47.9, 55.6, 58.5, 72.1, 72.5,
73.1, 75.4, 76.3, 78.2, 79.2, 80.5, 81.0, 84.6, 117.1 (d, J=23.5
Hz), 120.8 (d, J=21.4 Hz), 126.0, 130.4 (d, J=8.0 Hz), 131.3 (d,
J=7.5 Hz), 132.7, 143.1, 154.9, 155.7, 160.9, 164.2, 165.9, 170.3,
203.8; .sup.19F NMR, (CDCl.sub.3, 282 MHz) .delta. -84.15 (1F, dd,
J=25.4, 36.4 Hz), -86.17 (1F, d, J=36.7 Hz), -111.71 (1F, dd,
J=9.3, 14.6 Hz); HRMS (FAB.sup.+, m/z): Calcd. for
C.sub.41H.sub.50F.sub.3NO.sub.16.H.sup.+, 870.3154; Found
870.3146.
Example 16
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-chlorobenzoyl)-10-acet-
yldocetaxel, SB-T-12851-4 (III-51k)
Yield 57%; white solid; mp .degree. C.; [.alpha.].sub.D.sup.20
-72.93 (c 4.1, CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz):
.delta. 1.14 (3H, s, C-16), 1.25 (3H, m, C-17), 1.31 (9H, s, Boc),
1.67 (3H, s, H-19), 1.73 (1H, s, OH), 1.89 (4H, m, H-6b, H-18),
2.24 (3H, s, 10-OAc), 2.33 (2H, d, J=8.5 Hz, H-14), 2.39 (3H, s,
4-OAc), 2.51 (1H, d, J=3.5 Hz, OH), 2.55 (1H, ddd, J=6.5, 9.0, 15.0
Hz, H-6a), 3.51 (1H, bs, OH), 3.81 (1H, d, J=7.5 Hz, H-3), 4.15
(1H, d, J=8.5 Hz, H-20b), 4.29 (2H, m, H-2', H-20a), 4.41 (1H, dd,
J=6.5, 11.0 Hz, H-7), 4.58 (1H, ddd, J=1.0, 10.0, 24.5 Hz, H-3'
vinyl), 4.86 (1H, m, H-3'), 4.93 (1H, d, J=9.0 Hz, NH-3'), 4.98
(1H, d, J=7.5, H-5), 5.62 (1H, d, J=7.5 Hz, H-2), 6.21 (1H, t,
J=9.5 Hz, H-13), 6.30 (1H, s, H-10), 7.45 (1H, t, J=7.5 Hz), 7.58
(1H, dd, J=1.5, 8.5 Hz), 8.00 (1H, d, J=7.5 Hz), 8.12 (1H, s);
.sup.13C NMR (CDCl.sub.3, 125 MHz) .delta. 9.5, 14.8, 20.8, 21.8,
22.1, 26.7, 28.1, 35.4 (d, J=16.7 Hz), 43.1, 45.6, 58.5, 72.1,
72.5, 73.1, 75.5, 76.3, 79.2, 80.4, 80.9, 84.3, 128.2, 130.0,
130.3, 130.9, 132.9, 134.8, 142.2, 154.8, 165.7, 170.2, 171.2,
203.5; .sup.19F NMR, (CDCl.sub.3, 282 MHz) 8-84.15 (1F, dd, J=25.7,
36.7 Hz), -86.12 (1F, dd, J=36.7 Hz); HRMS (FAB+, m/z): Calcd. for
C.sub.41H.sub.50ClF.sub.2NO.sub.15.H.sup.+, 870.2910; Found,
870.2891.
Example 17
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-chlorobenzoyl)-10-cycl-
opropanecarbonyldocetaxel, SB-T-12852-4 (III-51l)
Yield 73%; white solid; mp .degree. C.; [.alpha.].sub.D.sup.20
-78.97 (c 5.8, CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 1.02 (2H, m, CH.sub.2-c-Pr), 1.15 (2H, m, CH.sub.2-c-Pr),
1.16 (3H, s, C-16), 1.28 (3H, m, C-17), 1.32 (9H, s, Boc), 1.68
(3H, s, H-19), 1.70 (1H, bs, OH), 1.80 (1H, m, CH-c-Pr), 1.86-1.89
(1H, m, H-6b), 1.89 (3H, s, H-18), 2.33 (2H, m, H-14), 2.41 (3H, s,
4-OAc), 2.56 (1H, ddd, J=7.0, 9.0, 15.0 Hz, H-6a), 2.59 (1H, bs,
OH), 3.51 (1H, bs, OH), 3.82 (1H, d, J=7.0 Hz, H-3), 4.16 (1H, d,
J=8.5 Hz, H-20b), 4.29 (1H, s, H-2'), 4.31 (1H, d, J=8.5 Hz,
H-20a), 4.41 (1H, dd, J=7.0, 10.5 Hz, H-7), 4.59 (1H, dd, J=9.0,
25.0 Hz, H-3' vinyl), 4.89 (1H, m, H-3'), 4.98 (2H, m, H-5, NH'),
5.63 (1H, d, J=7.0 Hz, H-7), 6.24 (1H, t, J=9.0 Hz, H-13), 6.31
(1H, s, H-10), 7.46 (2H, t, J=8.5 Hz), 7.60 (1H, dd, J=1.0, 7.0
Hz), 8.01 (1H, d, J=7.5 Hz), 8.13 (1H, s); .sup.13C NMR
(CDCl.sub.3, 100 MHz) .delta. 9.2, 9.4, 13.0, 14.9, 21.9, 22.2,
26.7, 28.1, 35.4, (d, J=7.9 Hz), 43.2, 45.6, 48.0, 58.5, 72.1,
72.6, 73.1, 75.3, 75.5, 76.3, 77.2, 79.2, 80.4, 81.0, 84.4, 128.3,
130.0, 130.3, 130.9, 133.0, 133.7, 134.8, 142.3, 154.8, 165.7,
170.2, 175.1, 203.7; .sup.19F NMR (CDCl.sub.3, 282 MHz) 5-84.15
(1F, dd, J=25.7, 34.7 Hz), -86.16 (1F, d, J=36.7 Hz); HRMS
(FAB.sup.+, m/z): Calcd. for
C.sub.43H.sub.52ClF.sub.2NO.sub.15.H.sup.+, 896.3066.
Found, 896.3036.
Example 18
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-chlorobenzoyl)-10-prop-
anoyldocetaxel, SB-T-12853-4 (III-51 m)
Yield 72%; white solid; [.alpha.].sub.D.sup.20 -76.73 (c 4.9,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.14 (3H,
s, H-16), 1.22-1.25 (6H, m, H-17, H-10-CH.sub.3), 1.31 (9H, s,
Boc), 1.67 (3H, s, H-19), 1.71 (1H, s, OH), 1.86-1.91 (4H, m, H-6b,
H-18), 2.32 (2H, m, H-14), 2.39 (3H, s, 4-OAc), 2.40-2.59 (3H, m,
H-6a, H-10, CH.sub.2), 3.49 (1H, bs, OH), 3.82 (1H, d, J=7.0 Hz,
H-3), 4.15 (2H, d, J=8.5 Hz, H-20b), 4.29 (2H, H-2', H-20a), 4.40
(1H, dd, J=6.0, 10.5 Hz, H-7), 4.58 (1H, ddd, J=1.5, 9.0, 24.5 Hz,
H-3'), 4.87 (1H, m, H-3'), 4.92 (1H, d, J=9.0 Hz, NH'-3'), 4.98
(1H, dd, J=1.5, 9.5 Hz, H-5), 5.62 (1H, d, J=7.5 Hz, H-2), 6.22
(1H, t, J=9.5 Hz, H-13), 6.31 (1H, s, H-10), 7.45 (1H, t, J=8.0
Hz), 7.45 (1H, ddd, J=1.0, 2.0, 8.0 Hz), 8.00 (1H, d, J=7.5 Hz),
8.12 (1H, s); .sup.13C NMR (CDCl.sub.3, 125 MHz) .delta. 8.9, 9.5,
14.9, 21.8, 22.2, 26.7, 27.5, 28.1, 35.5 (d, J 15.9 Hz), 43.2,
45.7, 58.5, 72.2, 72.6, 73.1, 75.3, 75.5, 76.3, 79.2, 80.4, 81.0,
84.4, 128.3, 130.1, 130.3, 130.9, 133.1, 133.7, 134.8, 142.1,
154.8, 165.7, 170.2, 174.6, 203.6; .sup.19F NMR (CDCl.sub.3, 282
MHz) 6-84.14 (1F, dd, J=23.7, 34.7 Hz), -86.13 (1F, d, J=36.7 Hz);
HRMS (FAB.sup.+, m/z): Calcd. for
C.sub.42H.sub.52ClF.sub.2NO.sub.15.H.sup.+, 884.3066; Found
884.3057.
Example 19
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-chlorobenzoyl)-10-dime-
thylcarbamoyldocetaxel, SB-T-12854-4 (III-51n)
Yield 91%; white solid; mp .degree. C.; [.alpha.].sub.D.sup.20
-88.09 (c 2.1, CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz):
.delta. 1.17 (3H, s, H-16), 1.27 (3H, m, H-17), 1.33 (9H, s, Boc),
1.62 (1H, bs, OH), 1.69 (3H, s, H-19), 1.84 (1H, m, OH), 1.90 (1H,
ddd, J=2.5, 11.5, 17.5 Hz, H-6b), 1.93 (3H, s, H-18), 2.34 (2H, m,
H-14), 2.42 (3H, s, 4-OAc), 2.56 (1H, ddd, J=6.0, 9.0, 15.0 Hz,
H-6a), 2.98 (3H, s, N-Me), 3.06 (3H, s, N-Me), 3.25 (1H, d, J=2.5
Hz, OH), 3.52 (1H, d, J=5.5 Hz, OH), 3.83 (1H, d, J=7.0 Hz, H-3),
4.18 (1H, d, J=8.5 Hz, H-20b), 4.29 (1H, s, H-2'), 4.32 (1H, d,
J=8.5 Hz, H-20a), 4.46 (1H, dd, J=6.5, 11.0 Hz, H-7), 4.58 (1H,
ddd, J=1.5, 10.0, 24.5 Hz, H-3' vinyl), 4.93 (2H, m, H-3', NH-3'),
5.01 (1H, d, J=10.0 Hz, H-5), 5.63 (1H, d, J=7.5 Hz, H-2), 6.25
(1H, t, J=9.0 Hz, H-13), 6.27 (1H, s, H-10), 7.47 (2H, t, J=7.5
Hz), 7.49 (1H, dd, J=1.0, 9.5 Hz), 7.82 (1H, d, J=8.0 Hz), 8.15
(1H, s); .sup.13C NMR (CDCl.sub.3, 125 MHz) .delta. 9.3, 14.9,
22.2, 26.9, 28.1, 35.4 (d, J=6.0 Hz), 36.0, 36.6, 43.2, 45.5, 58.5,
72.4, 72.6, 73.1, 75.6, 76.1, 76.3, 79.3, 80.4, 81.1, 84.6, 128.3,
130.1, 130.4, 130.9, 133.3, 133.7, 134.8, 142.6, 154.8, 156.1,
165.7, 171.1, 205.5; .sup.19F NMR, (CDCl.sub.3, 282 MHz) .delta.
-84.16 (1F, dd, J=23.9, 34.9 Hz), -86.17 (1F, d, J=36.7 Hz); HRMS
(FAB+, m/z): Calcd. for
C.sub.42H.sub.53ClF.sub.2N.sub.2O.sub.15.H.sup.+, 899.3175; Found
899.3151.
Example 20
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-chlorobenzoyl)-10-meth-
oxycarbonyldocetaxel, SB-T-12855-4 (III-51o)
Yield 70%; white solid; [.alpha.].sub.D.sup.20 -72.09 (c 4.3,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.16 (3H,
s, H-16), 1.26 (3H, m, H-17), 1.32 (9H, s, Boc), 1.63 (1H, bs, OH),
1.71 (3H, s, H-19), 1.91 (1H, m, H-6b), 1.94 (3H, s, H-18), 2.33
(2H, d, J=9.0 Hz, H-14), 2.42 (3H, s, 4-OAc), 2.46 (1H, d, J=4.0
Hz, OH), 2.59 (1H, ddd, J=7.5, 10.0, 15.5 Hz, H-6a), 3.46 (1H,
J=6.0 Hz, OH), 3.81 (1H, d, J=7.0 Hz, H-3), 3.87 (3H, s, H-10-MeO),
4.17 (1H, d, J=8.5 Hz, H-20b), 4.29 (1H, d, J=5.5 Hz, H-2'), 4.32
(1H, d, J=8.5 Hz, H-20a), 4.39 (1H, m, H-7), 4.59 (1H, dd, J=8.0,
24.5 Hz, H-3' vinyl), 4.89 (2H, m, H-3', NH-3'), 5.00 (1H, d, J=8.5
Hz, H-5), 5.64 (1H, d, J=7.5 Hz, H-2), 6.13 (1H, s, H-10), 6.23
(2H, t, J=8.5 Hz, H-13), 7.49 (1H, t, J=8.0 Hz), 7.60 (1H, d, J=7.5
Hz,), 8.01 (1H, d, J=8.0 Hz), 8.14 (1H, s); .sup.13C NMR
(CDCl.sub.3, 125 MHz) .delta. 9.4, 14.9, 21.7, 22.2, 26.6, 28.1,
35.3, 35.6, 43.1, 45.6, 55.6, 58.5, 72.1, 72.5, 73.2, 75.4, 76.3,
78.2, 79.2, 80.5, 80.9, 84.4, 128.3, 130.1, 130.3, 130.9, 132.6,
133.7, 134.9, 143.1, 154.9, 155.7, 165.7, 170.2, 203.8; .sup.19F
NMR (CDCl.sub.3, 282 MHz) 8-84.16 (1F, dd, J=23.7, 34.7 Hz), -86.17
(1F, dd, J=34.9 Hz); HRMS (FAB.sup.+, m/z): Calcd. for
C.sub.41H.sub.50ClF.sub.2NO.sub.16.H.sup.+, 886.2859; Found
886.2845.
Example 21
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-methoxybenzoyl)-10-ace-
tyldocetaxel, SB-T-12851-1 (III-51p)
Yield 76%; white solid; [.alpha.].sub.D.sup.20 -74.42 (c 2.15,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.15 (3H,
s, C-16), 1.26 (3H, m, C-17), 1.30 (9H, s, Boc), 1.68 (3H, s,
H-19), 1.76 (1H, s, OH), 1.88 (4H, m, H-6b, H-18), 2.24 (3H, s,
10-OAc), 2.33 (2H, m, H-14), 2.38 (3H, s, 4-OAc), 2.49 (1H, d,
J=3.5 Hz, OH), 2.56 (1H, ddd, J=6.5, 9.5, 15.0 Hz, H-6a), 3.47 (1H,
J=4.5 Hz, OH), 3.81 (1H, d, J=7.5 Hz, H-3), 3.90 (3H, s, 2-m-MeO),
4.15 (1H, d, J=8.0 Hz, H-20b), 4.27 (1H, s, H-2'), 4.36 (1H, d,
J=8.0 Hz, H-20a), 4.41 (1H, dd, J=6.0, 10.5 Hz, H-7), 4.58 (1H,
ddd, J=1.0, 9.5, 24.5 Hz, H-3'vinyl), 4.87-4.93 (2H, m, H-3',
NH-3'), 4.97 (1H, dd, J=2.0, 9.0, H-5), 5.67 (1H, d, J=7.5 Hz,
H-2), 6.24 (1H, t, J=8.5 Hz, H-13), 6.30 (1H, s, H-10), 7.15 (1H,
dd, J=2.0, 8.0 Hz), 7.40 (1H, t, J=7.5 Hz), 7.45 (1H, s), 7.72 (1H,
d, J=8.0 Hz); .sup.13C NMR (CDCl.sub.3, 100 MHz) .delta. 9.5, 14.8,
20.8, 21.8, 22.3, 26.7, 28.1, 35.5 (d, J=12.2 Hz), 43.2, 45.6,
55.3, 58.5, 72.1, 72.7, 73.1, 75.1, 75.5, 76.4, 77.2, 79.0, 80.5,
81.2, 84.4, 114.0, 120.7, 122.7, 129.7, 130.3, 133.1, 142.1, 154.8,
159.7, 166.9, 170.2, 171.2, 203.5; .sup.19F NMR (CDCl.sub.3, 282
MHz) .delta. -84.55 (1F, dd, J=33.8, 36.4 Hz), -86.24 (1F, dd,
J=36.4 Hz); HRMS (FAB.sup.+, m/z): Calcd. for
C.sub.42H.sub.53F.sub.2NO.sub.16.H.sup.+, 866.3405.
Found, 866.3439.
Example 22
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-methoxybenzoyl)-10-cyc-
lopropanecarbonyldocetaxel, SB-T-12852-1 (III-51q)
Yield 99%; white solid; [.alpha.].sub.D.sup.20 -77.03 (c 5.79,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 0.99 (2H,
m, CH.sub.2-c-Pr), 1.10 (2H, m, CH.sub.2-c-Pr), 1.15 (3H, s, C-16),
1.25 (3H, m, C-17), 1.28 (9H, s, Boc), 1.66 (3H, s, H-19),
1.74-1.81 (2H, m, CH-c-Pr, OH), 1.83-1.89 (1H, m, H-6b), 1.87 (3H,
s, H-18), 2.31 (2H, m, H-14), 2.37 (3H, s, 4-OAc), 2.53 (1H, ddd,
J=6.5, 9.5, 15.0 Hz, H-6a), 2.59 (1H, d, J=3.5 Hz, OH), 3.55 (1H,
bs, OH), 3.79 (1H, d, J=7.5 Hz, H-3), 3.88 (3H, s, m-MeO-H-2), 4.16
(1H, d, J=8.5 Hz, H-20b), 4.26 (1H, d, J=2.5 Hz, H-2'), 4.34 (1H,
d, J=8.5 Hz, H-20a), 4.40 (1H, m, H-7), 4.57 (1H, dd, J=10.0, 24.5
Hz, H-3' vinyl), 4.86 (1H, t, J=8.5 Hz, H-3'), 4.96 (2 H, m, H-5,
NH'), 5.65 (1H, d, J=7.0 Hz, H-7), 6.23 (1H, t, J=9.0 Hz, H-13),
6.28 (1H, s, H-10), 7.13 (1H, ddd, J=2.0, 3.0, 8.0 Hz), 7.38 (2H,
t, J=7.5 Hz), 7.63 (1H, s), 7.79 (1H, d, J=7.5 Hz); .sup.13C NMR
(CDCl.sub.3, 125 MHz) .delta. 9.2, 9.4, 9.5, 13.0, 14.8, 22.0, 22.3
(d, J=2.9 Hz), 26.7, 28.1, 35.5, (d, J=4.3 Hz), 43.2, 45.6, 55.3,
58.5, 72.1, 72.6, 73.1, 75.1, 75.3, 76.4, 77.2, 79.0, 80.4, 81.0,
84.4, 114.0, 120.6, 122.7, 129.7, 130.3, 133.2, 142.1, 154.8,
156.4, 159.7, 166.9, 170.2, 172.4, 175.1, 203.8; .sup.19F NMR
(CDCl.sub.3, 282 MHz) .delta. -84.62 (1F, dd, J=25.7, 36.7 Hz),
-86.29 (1F, d, J=36.4 Hz); HRMS (FAB.sup.+, m/z): Calcd. for
C.sub.44H.sub.55F.sub.2NO.sub.16.H.sup.+, 892.3562; Found,
892.3599.
Example 23
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-methoxybenzoyl)-10-pro-
panoyldocetaxel. SB-T-12853-1 (III-51r)
Yield 58%; white solid; [.alpha.].sub.D.sup.20 -79.78 (c 3.66,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.15 (3H,
s, H-16), 1.22-1.25 (6H, m, H-17, H-10-CH.sub.3), 1.30 (9H, s,
Boc), 1.67 (3H, s, H-19), 1.71 (1H, s, OH), 1.79 (1H, s, OH),
1.86-1.91 (4H, m, H-6b, H-18), 2.32 (2H, m, H-14), 2.38 (3H, s,
4-OAc), 2.38-2.59 (3H, m, H-6a, H-10, CH.sub.2), 3.52 (1H, bs, OH),
3.82 (1H, d, J=7.0 Hz, H-3), 3.89 (H, m-MeO-H2), 4.18 (2H, d, J=8.5
Hz, H-20b), 4.27 (1H, H-2'), 4.35 (1H, d, J=8.5 Hz, H-20a), 4.40
(1H, dd, J=6.5, 11.0 Hz, H-7), 4.58 (1H, ddd, J=1.5, 10.0, 25.0 Hz,
H-3'), 4.87 (1H, t, J=9.0 Hz, H-3'), 4.96 (2H, m, NH'-3', H-5),
5.66 (1H, d, J=6.5 Hz, H-2), 6.24 (1H, t, J=9.0 Hz, H-13), 6.31
(1H, s, H-10), 7.15 (1H, ddd, J=1.0, 2.5, 8.5 Hz), 7.39 (1H, t,
J=7.5 Hz), 7.65 (1H, s), 7.71 (1H, d, J=8.0 Hz); .sup.13C NMR
(CDCl.sub.3, 125 MHz) .delta. 9.0, 9.5, 14.8, 21.9, 22.3, 26.7,
27.5, 28.1, 35.4 (d, J=15.9 Hz), 43.2, 45.6, 55.3, 58.3, 72.1,
72.6, 73.1, 75.1, 75.3, 76.4, 77.2, 79.0, 81.1, 84.4, 114.0, 122.7,
129.7, 130.3, 133.2, 141.9, 154.8, 159.7, 166.9, 170.2, 174.6,
203.7; .sup.19F NMR, (CDCl.sub.3, 282 MHz) .delta. -84.58 (1F, dd,
J=25.7, 36.7 Hz), -86.26 (1F, d, J=36.7 Hz); HRMS (FAB.sup.+, m/z):
Calcd. for C.sub.43H.sub.55F.sub.2NO.sub.16.H.sup.+, 880.3562;
Found 880.3578.
Example 24
3'-dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-methoxybenzoyl)-10-dim-
ethylcarbamate-docetaxel, ST-T-12854-1 (III-51s)
Yield 74%; white solid; .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta.
1.15 (3H, s, H-16), 1.25 (3H, s, H-17), 1.29 (9H, s, Boc), 1.67
(3H, s, H-19), 1.76 (1H, bs, OH), 1.88 (1H, m, H-6b), 1.89 (3H, s,
H-18), 2.31 (2H, m, H-14), 2.38 (3H, s, 4-OAc), 2.53 (1H, ddd,
J=6.5, 10.0, 15.0 Hz, H-6a), 2.96 (3H, s, N-Me), 3.04 (3H, s,
N-Me), 3.52 (1H, bs, OH), 3.81 (1H, d, J=7.0 Hz, H-3), 3.90 (3H, s,
m-MeO-H2), 4.17 (1H, d, J=8.0 Hz, H-20b), 4.27 (1H, s, H-2'), 4.35
(1H, d, J=8.0 Hz, H-20a), 4.45 (1H, dd, J=6.0, 10.5 Hz, H-7), 4.58
(1H, ddd, J=1.5, 10.0, 25.0 Hz, H-3' vinyl), 4.87 (1H, t, J=8.5 Hz,
H-3'), 4.97 (1H, m, H-5, NH-3'), 5.65 (1H, d, J=7.0 Hz, H-2), 6.25
(2H, m, H-10, H-13), 7.14 (1H, dd, J=1.5, 7.5 Hz), 7.39 (2H, t,
J=8.0 Hz), 7.65 (1H, s), 7.71 (1H, d, J=7.5 Hz); .sup.13C NMR
(CD+Cl.sub.3, 125 MHz) .delta. 9.3, 14.9, 22.3, 26.9, 28.1, 35.4
(d, J=12.9 Hz), 36.0, 36.6, 43.2, 45.5, 55.3, 58.5, 72.4, 72.7,
73.1, 75.2, 76.1, 76.4, 79.2, 80.4, 81.2, 84.6, 114.0. 120.7,
122.7, 129.7, 130.3, 133.5, 133.7, 142.4, 154.8, 156.1, 159.7,
166.9, 170.1, 205.6; .sup.19F NMR (CDCl.sub.3, 282 MHz) 8-84.60
(1F, dd, J=23.9, 34.9 Hz), -86.30 (1F, d, J=36.4 Hz); HRMS
(FAB.sup.+, m/z): Calcd. For
C.sub.43H.sub.56F.sub.2N.sub.2O.sub.16.H.sup.+, 895.3671; Found
895.3676.
Example 25
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-methoxybenzoyl)-10-met-
hoxycarbonyldocetaxel, SB-T-12855-1 (III-51t)
Yield 89%; white solid; [.alpha.].sub.D.sup.20 -68.98 (c 4.61,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.15 (3H,
s, H-16), 1.24 (3H, m, H-17), 1.29 (9H, s, Boc), 1.69 (3H, s,
H-19), 1.78 (1H, bs, OH), 1.88 (1H, m, H-6b), 1.91 (3H, s, H-18),
2.32 (2H, m, H-14), 2.38 (3H, s, 4-OAc), 2.49 (1H, d, J=4.5 Hz,
OH), 2.56 (1H, ddd, J=7.0, 9.5, 15.0 Hz, H-6a), 3.53 (1H, J=5.5 Hz,
OH), 3.78 (1H, d, J=6.5 Hz, H-3), 3.87 (3H, s, H-10-MeO), 3.89 (3H,
s, m-MeO-H2), 4.18 (1H, d, J=8.5 Hz, H-20b), 4.27 (1H, d, J=3.0 Hz,
H-2'), 4.36 (1H, d, J=8.5 Hz, H-20a), 4.41 (1H, m, H-7), 4.59 (1H,
dd, J=9.5, 24.5 Hz, H-3' vinyl), 4.86 (1H, t, J=9.0 Hz, H-3'), 4.95
(2H, m, H-5, NH-3'), 5.66 (1H, d, J=7.5 Hz, H-2), 6.12 (1H, s,
H-10), 6.24 (1H, t, J=8.5 Hz, H-13), 7.15 (1H, d, J=2.0, 7.5 Hz),
7.39 (1H, t, J=8.0 Hz), 7.64 (1H, s), 7.71 (1H, d, J=7.0 Hz);
.sup.13C NMR (CDCl.sub.3, 125 MHz) .delta. 9.5, 14.9, 21.8, 22.3,
26.6, 28.1, 35.3 (d, J=22.0 Hz), 43.1, 45.6, 55.6, 55.6, 58.5,
72.0, 72.6, 73.1, 75.0, 77.2, 78.2, 79.0, 80.5, 81.1, 84.4, 114.0,
120.7, 129.7, 130.3, 132.8, 142.9, 154.8, 155.7, 159.7, 166.9,
170.3, 203.9; .sup.19F NMR (CDCl.sub.3, 282 MHz) .delta. -84.60
(1F, dd, J=25.7, 36.7 Hz), -86.27 (1F, dd, J=36.7 Hz); HRMS
(FAB.sup.+, m/z): Calcd. for
C.sub.42H.sub.53F.sub.2NO.sub.17.H.sup.+, 882.3354; Found
882.3353.
Example 26
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-azidobenzoyl)-10-acety-
ldocetaxel, SB-T-12851-3 (III-51u)
Yield 49%; white solid; [.alpha.].sub.D.sup.20 -70.59 (c 3.23,
CHCl.sub.3); .sup.1HNMR (CDCl.sub.3, 400 MHz): .delta. 1.15 (3H, s,
C-16), 1.26 (3H, s, C-17), 1.30 (9H, s, Boc), 1.67 (3H, s, H-19),
1.69 (1H, bs, OH), 1.88 (4H, m, H-6b, H-18), 2.24 (3H, s, 10-OAc),
2.32 (2H, m, H-14), 2.39 (3H, s, 4-OAc), 2.49 (1H, bs, OH), 2.56
(1H, ddd, J=7.0, 9.5, 15.0 Hz, H-6a), 3.48 (1H, J=4.0 Hz, OH), 3.82
(1H, d, J=7.0 Hz, H-3), 4.16 (1H, d, J=8.5 Hz, H-20b); 4.26 (1H, s,
H-2'), 4.33 (1H, d, J=8.5 Hz, H-20a), 4.42 (1H, dd, J=6.5, 10.5 Hz,
H-7), 4.57 (1H, ddd, J=1.5, 9.5, 25.0 Hz, H-3' vinyl), 4.85 (1H, t,
J=8.5 Hz, H-3'), 4.93 (1H, d, J=9.5 Hz, NH-3'), 4.98 (1H, d, J=7.5,
1'-5), 5.66 (1H, d, J=7.5 Hz, H-2), 6.22 (1H, t, J=9.0 Hz, H-13),
6.29 (1H, s, H-10), 7.23 (111, dd, J=1.5, 8.0 Hz), 7.48 (1H, t,
J=8.0 Hz), 7.81 (1H, s), 7.89 (1H, d, J=8.0 Hz); .sup.13C NMR
(CDCl.sub.3, 100 MHz) .delta. 9.5, 14.9, 20.8, 21.9, 22.4, 26.7,
28.1, 35.5 (d, J=15.1 Hz), 43.2, 45.6, 58.5, 72.1, 72.6, 73.1,
75.4, 75.5, 76.4, 79.1, 80.4, 81.0, 84.4, 120.1, 124.4, 126.7,
130.2, 133.0, 140.9, 142.2, 154.8, 166.1, 170.3, 171.2, 203.6;
.sup.19F NMR, (CDCl.sub.3, 282 MHz) .delta. -83.99 (1F, dd, J=25.7,
36.7 Hz), -86.12 (1F, d, J=35.0 Hz); HRMS (FAB.sup.+, m/z): Calcd.
for C.sub.41H.sub.50F.sub.2N.sub.4O.sub.15.H.sup.+, 877.3314;
Found, 877.3351.
Example 27
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-azidobenzoyl)-10-cyclo-
propanecarbonyldocetaxel, SB-T-12852-3 (III-51w)
Yield 78%; white solid; [.alpha.].sub.D.sup.20 -67.39 (c 5.09,
CHCl.sub.3); .sup.1H NMR(CDCl.sub.3, 400 MHz): .delta. 1.02 (2H, m,
CH.sub.2-c-Pr), 1.15 (2H, m, CH.sub.2-c-Pr), 1.17 (3H, s, C-16),
1.28 (3H, m, C-17), 1.32 (9H, s, Boc), 1.68 (3H, s, H-19), 1.76
(1H, bs, OH), 1.79 (1H, m, CH-c-Pr), 1.86-1.91 (111, m, H-6b), 1.90
(3H, s, H-18), 2.34 (2H, m, H-14), 2.41 (3H, s, 4-OAc), 2.56 (1H,
ddd, J=6.5, 9.5, 15.0 Hz, H-6a), 2.62 (1H, bs, OH), 3.54 (1H, d,
J=5.5 Hz, OH), 3.83 (1H, d, J=7.5 Hz, H-3), 4.18 (1H, d, J=8.5 Hz,
H-20b), 4.28 (1H, d, 3.0 Hz, H-2'), 4.35 (1H, d, J=8.5 Hz, H-20a),
4.43 (1H, dd, J=6.5, 10.0 Hz, H-7), 4.58 (1H, ddd, J=1.5, 9.0, 24.5
Hz, H-3' vinyl), 4.87 (1H, t, J=8.5 Hz, H-3'), 4.98 (2 H, m, H-5,
NH-3'), 5.67 (1H, d, J=7.0 Hz, H-7), 6.24 (1H, t, J=8.0 Hz, H-13),
6.31 (1H, s, H-10), 7.25 (1H, dd, J=1.5, 8.0 Hz), 7.49 (2H, t,
J=8.0 Hz), 7.82 (1H, s), 7.90 (1H, d, J=8.0 Hz); .sup.13C NMR
(CDCl.sub.3, 100 MHz) .delta. 9.2, 9.4, 9.5, 13.0, 14.9, 22.0,
22.3, 26.7, 28.1, 35.5, (d, J=7.6 Hz), 43.2, 45.6, 58.5, 72.1,
72.6, 73.1, 75.3, 75.5, 76.4, 79.1, 80.4, 81.0, 84.5, 120.1, 124.4,
126.7, 130.2, 130.8, 133.1, 140.9, 142.3, 154.8, 166.1, 170.3,
175.1, 203.7; .sup.19F NMR (CDCl.sub.3, 282 MHz) .delta. -84.02
(1F, dd, J=25.7, 34.9 Hz), -86.14 (1F, d, J=34.9 Hz); HRMS
(FAB.sup.+, m/z): Calcd. for
C.sub.43H.sub.52F.sub.2N.sub.4O.sub.15.H.sup.+, 903.3470; Found,
903.3469.
Example 28
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-azidobenzoyl)-10-propa-
noyldocetaxel, SB-T-12853-3 (III-51x)
Yield 93%; white solid; [.alpha.].sub.D.sup.20 -67.77 (c 3.32,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.14 (3H,
s, H-16), 1.22-1.25 (6H, m, H-17, H-10-CH.sub.3), 1.30 (9H, s,
Boc), 1.67 (3H, s, H-19), 1.71 (1H, s, OH), 1.69 (1H, s, OH),
1.85-1.91 (4H, m, H-6b, H-18), 2.32 (2H, m, H-14), 2.39 (3H, s,
4-OAc), 2.47-2.59 (3H, m, H-6a, H-10, CH.sub.2), 3.48 (1H, d, J=4.5
Hz, OH), 3.82 (1H, d, J=7.5 Hz, H-3), 4.16 (1H, d, J=8.5 Hz,
H-20b), 4.26 (1H, H-2'), 4.33 (1H, d, J=8.5 Hz, H-20a), 4.43 (1H,
dd, J=7.0, 11.0 Hz, H-7), 4.56 (1H, ddd, J=1.5, 9.0, 24.5 Hz,
H-3'), 4.86 (1H, t, J=8.0 Hz, H-3'), 4.92 (1H, d, J=9.5 Hz,
NH'-3'), 4.98 (1H, d, J=8.0 Hz, H-5), 5.66 (1H, d, J=7.5 Hz, H-2),
6.22 (1 H, t, J=8.0 Hz, H-13), 6.31 (1H, s, H-10), 7.23 (1H, dd,
J=1.5, 7.5 Hz), 7.48 (1H, t, J=7.5 Hz), 7.81 (1H, s), 7.89 (1H, d,
J=8.0 Hz); .sup.13C NMR (CDCl.sub.3, 125 MHz) .delta. 9.0, 9.5,
14.9, 21.7, 22.4, 26.7, 27.5, 28.1, 35.5 (d, J=11.5 Hz), 43.2,
45.6, 58.5, 72.1, 72.6, 73.1, 75.1, 75.3, 75.4, 76.4, 79.1, 81.0,
84.5, 120.1, 124.4, 126.7, 130.2, 130.8, 133.2, 140.9, 154.8,
159.7, 166.1, 170.3, 174.6, 203.7; .sup.19F NMR (CDCl.sub.3, 282
MHz) 8-83.99 (1F, dd, J=25.7, 34.7 Hz), -86.12 (1F, d, J=36.7 Hz);
FIRMS (FAB.sup.+, m/z): Calcd. for
C.sub.42H.sub.52F.sub.2N.sub.4O.sub.15.H.sup.+, 891.3470; Found
891.3473.
Example 29
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-azidobenzoyl)-10-dimet-
hylcarbamoyldocetaxel, SB-T-12854-3 (III-51y)
Yield 79%; white solid; [.alpha.].sub.D.sup.20 -75.39 (c 4.51,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 500 MHz): .delta. 1.15 (3H,
s, H-16), 1.25 (3H, s, H-17), 1.30 (9H, s, Boc), 1.66 (3H, s,
H-19), 1.75 (1H, bs, OH), 1.87 (1H, m, H-6b), 1.90 (3H, s, H-18),
2.31 (2H, m, H-14), 2.39 (3H, s, 4-OAc), 2.54 (1H, ddd, J=7.0,
10.0, 15.5 Hz, H-6a), 2.96 (3H, s, N-Me), 3.04 (3H, s, N-Me), 3.56
(1H, bs, OH), 3.81 (1H, d, J=7.0 Hz, H-3), 4.16 (1H, d, J=8.5 Hz,
H-20b), 4.27 (1H, s, H-2'), 4.32 (1H, d, J=8.5 Hz, H-20a), 4.45
(1H, dd, J=6.5, 10.5 Hz, H-7), 4.57 (1H, ddd, J=1.0, 9.0, 24.0 Hz,
H-3' vinyl), 4.85 (1H, t, J=8.0 Hz, H-3'), 4.97 (2H, m, H-5,
NH-3'), 5.65 (1H, d, J=7.0 Hz, H-2), 6.23 (1H, t, J=9.5 Hz, H-13),
6.25 (1H, s, H-10), 7.23 (1H, dd, J=1.5, 8.5 Hz), 7.47 (1H, t,
J=8.0 Hz), 7.80 (1H, s), 7.89 (1H, d, J=8.0 Hz); .sup.13C NMR
(CDCl.sub.3, 125 MHz) .delta. 9.3, 14.9, 22.3, 26.9, 28.1, 35.4 (d,
J=6.6 Hz), 36.0, 36.6, 43.2, 58.5, 72.4, 72.6, 73.1, 75.6, 76.1,
76.3, 79.2, 80.1, 84.7, 120.7, 120.2, 124.3, 126.7, 130.2, 130.9,
133.4, 140.9, 142.6, 154.9, 156.1, 166.1, 170.3, 205.5; .sup.19F
NMR (CDCl.sub.3, 282 MHz) 6-84.06 (1F, dd, J=25.7, 34.7 Hz), -86.17
(1F, d, J=36.7 Hz); HRMS (FAB.sup.+, m/z): Calcd. for
C.sub.42H.sub.53F.sub.2N.sub.5O.sub.15.H.sup.+, 906.3579; Found
906.3588.
Example 30
3'-Dephenyl-3'-(2,2-difluorovinyl)-2-debenzoyl-2-(3-azidobenzoyl)-10-metho-
xycarbonyldocetaxel, SB-T-12855-3 (III-51z)
Yield 77%; white solid; [.alpha.].sub.D.sup.20 -66.67 (c 3.9,
CHCl.sub.3); .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 1.15 (3H,
s, H-16), 1.24 (3H, s, H-17), 1.29 (9H, s, Boc), 1.69 (3H, s,
H-19), 1.71 (1H, bs, OH), 1.89 (1H, m, H-6b), 1.92 (3H, s, H-18),
2.32 (2H, m, H-14), 2.39 (3H, s, 4-OAc), 2.49 (1H, bs, OH), 2.56
(1H, ddd, J=6.5, 9.5, 14.5 Hz, H-6a), 3.51 (1H, bs, OH), 3.79 (1H,
d, J=7.0 Hz, H-3), 3.87 (3H, s, H-10-MeO), 4.17 (1H, d, J=8.5 Hz,
H-20b), 4.26 (1H, s, H-2'), 4.33 (1H, d, J=8.5 Hz, H-20a), 4.40
(1H, dd, J=7.0, 11.0 Hz, H-7), 4.57 (1H, ddd, J=1.0, 9.0, 24.5 Hz,
H-3' vinyl), 4.85 (1H, t, J=8.5 Hz, H-3'), 4.96 (2H, m, H-5,
NH-3'), 5.66 (1H, d, J=7.5 Hz, H-2), 6.12 (1H, s, H-10), 6.22 (1H,
t, J=9.0 Hz, H-13), 7.23 (1H, dd, J=1.5, 6.5 Hz), 7.48 (1H, t,
J=7.5 Hz), 7.81 (1H, s), 7.89 (1H, d, J=8.0 Hz); .sup.13C NMR
(CDCl.sub.3, 100 MHz) .delta. 9.5, 14.9, 21.8, 22.4, 26.6, 28.1,
35.4 (d, J=18.6 Hz), 43.1, 45.6, 55.6, 55.6, 58.5, 72.0, 72.5,
73.1, 75.4, 76.3, 78.2, 79.1, 80.4, 81.0, 84.3, 120.1, 124.4,
126.7, 130.2, 130.8, 132.7, 140.9, 143.0, 154.7, 155.7, 166.1,
170.4, 203.8; .sup.19F NMR (CDCl.sub.3, 282 MHz) .delta. -84.01
(1F, dd, J=25.7, 36.7 Hz), -86.13 (1F, d, J=36.7 Hz); HRMS
(FAB.sup.+, m/z): Calcd. for
C.sub.41H.sub.50F.sub.2N.sub.4O.sub.16.H.sup.+, 893.3263; Found
893.3269.
Example 31
Tumor Growth Inhibitory Activity of Fluorotaxoids
Fluorotaxoids were evaluated in their tumor growth inhibitory
activities against human tumor cell lines, MCF7 (mammary carcinoma)
or MCF7-R (mammary carcinoma cells 250-fold resistant to
paclitaxel), after 72 h drug exposure according to literature
methods. Results are shown for some selected compounds in the
tables below.
In the tables, lower numbers indicate higher potency (or greater
activity). Paclitaxel was used as the standard for comparison. The
data represent the mean values of at least three separate
experiments.
TABLE-US-00002 Cytotoxicity (IC.sub.50 nM) of
CF.sub.2.dbd.CH-Taxoids (1) ##STR00014## MCF7 MCF7-R
CF.sub.2.dbd.CH-Taxoid R X (breast) (breast) R/S Paclitaxel Me H
1.2 300 250 SB-T-12851 Me H 0.099 0.95 9.6 SB-T-12852 cyclo-Pr H
0.12 6.03 53 SB-T-12853 Et H 0.12 1.2 10 SB-T-12854 Me.sub.2N H
0.13 4.27 33 SB-T-12855 MeO H 0.14 1.29 9.2
TABLE-US-00003 Cytotoxicity (IC.sub.50 nM) of
CF.sub.2.dbd.CH-Taxoids (2) ##STR00015## MCF7 MCF7-R
CF.sub.2.dbd.CH-Taxoid R X (breast) (breast) R/S Paclitaxel Me H
1.2 300 250 SB-T-12851-1 Me MeO 0.25 1.5 6.0 SB-T-12852-1 cyclo-Pr
MeO 0.092 0.48 5.2 SB-T-12853-1 Et MeO 0.34 0.57 1.7 SB-T-12854-1
Me.sub.2N MeO 0.11 0.96 8.7 SB-T-12855-1 MeO MeO 0.078 0.50 6.4
TABLE-US-00004 Cytotoxicity (IC.sub.50 nM) of
CF.sub.2.dbd.CH-Taxoids (3) ##STR00016## MCF7 MCF7-R
CF.sub.2.dbd.CH-Taxoid R X (breast) (breast) R/S Paclitaxel Me H
1.2 300 250 SB-T-12851-2 Me F 0.13 1.53 12 SB-T-12852-2 cyclo-Pr F
0.076 1.72 23 SB-T-12853-2 Et F 0.23 2.54 11 SB-T-12854-2 Me.sub.2N
F 0.17 2.25 9.4 SB-T-12855-2 MeO F 0.12 1.85 11
TABLE-US-00005 Cytotoxicity (IC.sub.50 nM) of
CF.sub.2.dbd.CH-Taxoids (4) ##STR00017## MCF7 MCF7-R
CF.sub.2.dbd.CH-Taxoid R X (breast) (breast) R/S Paclitaxel Me H
1.2 300 250 SB-T-12851-3 Me N.sub.3 0.092 0.34 3.7 SB-T-12852-3
cyclo-Pr N.sub.3 0.092 0.45 4.9 SB-T-12853-3 Et N.sub.3 0.13 0.38
2.9 SB-T-12854-3 Me.sub.2N N.sub.3 0.13 0.45 3.7 SB-T-12855-3 MeO
N.sub.3 0.076 0.40 5.3
TABLE-US-00006 Cytotoxicity (IC.sub.50 nM) of
CF.sub.2.dbd.CH-Taxoids (5) ##STR00018## MCF7 MCF7-R
CF.sub.2.dbd.CH-Taxoid R X (breast) (breast) R/S Paclitaxel Me H
1.2 300 250 SB-T-12851-4 Me Cl 0.13 0.70 5.4 SB-T-12852-4 cyclo-Pr
Cl 0.12 0.50 4.2 SB-T-12853-4 Et Cl 0.13 0.45 3.5 SB-T-12854-4
Me.sub.2N Cl 0.93 2.6 2.8 SB-T-12855-4 MeO Cl 0.099 1.15 12
Assessment of cell growth inhibition was determined according to
the methods of Skehan et al (See Skehan et al., J. Nat. Cancer
Inst., 82, 1107 (1990)). Briefly, cells were plated between 400 and
1200 cells/well in 96 well plates and incubated at 37.degree. C.
for 15-18 h prior to drug addition to allow attachment of cells.
Compounds tested were solubilized in 100% DMSO and further diluted
in RPMI-1640 containing 10 mM HEPES. Each cell line was treated
with 10 concentrations of compounds (5 log range). After a 72 h
incubation, 100 .mu.L of ice-cold 50% TCA was added to each well
and incubated for 1 h at 4.degree. C. Plates were then washed 5
times with tap water to remove TCA, low-molecular-weight
metabolites and serum proteins. Sulforhodamine B (SRB) (0.4%, 50
.mu.L) was added to each well. Following a 5 minute incubation at
room temperature, plates were rinsed 5 times with 0.1% acetic acid
and air dried. Bound dye was solubilized with 10 mM Tris Base (pH
10.5) for 5 min on a gyratory shaker. Optical density was measured
at 570 nm.
Data were fit with the Sigmoid-Emax concentration-effect model with
non-linear regression, weighted by the reciprocal of the square of
the predicted response (see Holford, N. H. G.; Scheiner, L. B.,
"Understanding the dose-effect relationship: Clinical applications
of pharmaco-kinetic-pharmacodynamic models," Clin. Pharmacokin., 6,
429-453 (1981)). The fitting software was developed by the Roswell
Park Cancer Institute with Microsoft FORTRAN, and uses the
Marquardt algorithm (see Marquardt, D. W., "An algorithm for least
squares estimation of nonlinear parameters," J. Soc. Ind. Appl.
Math., 11, 431-441 (1963)) as adopted by Nash for the non-linear
regression (see Nash, J. C., "Compact numerical method for
computers: Linear algebra and function minimization," John Wiley
& Sons, New York, 1979). The concentration of drug which
resulted in 50% growth inhibition (IC.sub.50) was calculated.
Thus, while there have been described what are presently believed
to be the preferred embodiments of the present invention, those
skilled in the art will realize that other and further embodiments
can be made without departing from the spirit of the invention, and
it is intended to include all such further modifications and
changes as come within the true scope of the claims set forth
herein.
* * * * *